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Abstract 
In 2014, there were 850,000 people living with dementia in the UK, creating an economic burden of 
£26.3 billion a year. 62% of dementia patients are diagnosed with Alzheimer’s Disease (AD). AD is a 
slow progressing disease with three phases: a long prodromal stage followed by mild cognitive 
impairment and then late AD. The prodromal phase of AD is on average 30 years. So, when the first 
symptoms become apparent, the pathology in the brain is extensive. If Alzheimer’s could be diagnosed 
early, when the pathological load is lower, this may improve the chances of finding a disease modifying 
therapy.  
For diagnosis during the prodromal stage to be viable, patients would need to be diagnosed through 
mass screening, with the most appropriate diagnosis method being biomarker detection in peripheral 
blood. There are an increasing number of articles in literature researching the use of non-coding RNA 
sequences called microRNA (miRNA) as biomarkers for AD. However, their viability in diagnosing 
prodromal AD is unknown and the current miRNA detection method, the polymerase chain reaction 
(PCR), is time consuming, expensive and requires experienced personnel, making it unsuitable for use 
in mass screening. Therefore, the aim of the thesis was to investigate miRNA as a prodromal biomarker 
with a new detection method to determine the usability of miRNA as a prodromal AD biomarker.  
AD is characterised by the build-up of amyloid-β and hyper-phosphorylated tau in the brain. The 
movement of tau through the brain is divided into 6 Braak stages. Chapter 4 aimed to determine the 
point at which miRNAs deregulate in AD. To achieve this, post-mortem brain tissue was obtained 
through all 6 Braak stages. The RNA from the post-mortem brain samples were isolated and the 
change in miRNA levels were determined using PCR and the ΔΔct method. After comparing miRNA to 
a spike in control the 4 miRNAs tested showed no significant change in miRNA levels through the 
progression of AD. 
ii 
 
One of the first signs of AD is the activation of astrocytes in the brain. The aim of Chapter 5 was to 
determine the effect of the deregulated miRNAs on astrocytes. An astrocytoma cell line was activated 
using lipopolysaccharides and TNF-α then transfected so specific miRNA were over-expressed. The 
concentration of metabolites, cytokines and growth factors were measured in the cell supernatant. 
Results showed mir-210 regulated G-CSF and mir-223 regulated glutamate consumption.  
Finally, the feasibility of rapid detection of miRNA was investigated using a quartz crystal microblance 
(QCM). The QCM, assembled within a custom-built microfluidic flow cell, was driven at its fundamental 
resonance frequency. Shifts in the third Fourier harmonic current and the resonance frequency were 
measured for a range of concentrations of a single-stranded DNA (ssDNA). The results show feasibility 
for rapid quantitative detection of ssDNA to 60 ng/mL, in an easy-to-use label-free assay. Amplification 
of the signal was seen with the addition of electrochemical potential and the use of particles.  
Results looking at the deregulation of miRNA in the temporal cortex showed no significant change, 
therefore further work is needed looking at alternative miRNA sequences. The results with ssDNA 
suggest that quartz crystal resonator has the potential for rapid, specific and quantitative miRNA 
detection. However, amplification strategies would help to achieve the clinically relevant limit of 
detection in peripheral blood. 
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1.1 Introduction  
Dementia is a common syndrome for the elderly, over 65 years old, that leads to a decline in memory 
and difficulties in thinking, problem solving or language [2]. In 2014 there were 850,000 people living 
with dementia in the UK, with an economic burden of £26.3 billion a year [3]. Due to the increasing 
age of the population, the number of people effected is set to rise to over 1.1 million people by 2025 
[3]. The most common form of dementia is Alzheimer’s Disease (AD), accounting for 62% of those 
diagnosed with dementia [3]. Currently there is no cure, or prevention, however symptomatic 
treatments do exist [4].  
The first point of contact for a patient experiencing symptoms of AD is their General Practitioner (GP). 
The patient will then be referred to a memory clinic, of which there is estimated to be 222 in the UK 
[5]. On average it takes 14 weeks from the  GP referral to receiving a diagnosis [5]. In total it can take 
18 to 30 months between the onset of the first symptoms and a diagnosis [6]. Memory clinics conduct 
blood tests, neuropsychological assessments, neuro-imaging and clinical assessments to screen for 
any other causes of memory impairment [7]. It is estimated that only 59% of people with dementia 
have a diagnosis, this could be due to the stigma attached to dementia, that dementia is currently 
incurable or not being recognised in those at risk [8].   
At the onset of first symptoms, a patient will have been developing AD pathology in the brain for an 
average of 30 years [9]. Then it would take a further 30 months for a diagnosis. If diagnosed earlier, 
before onset of symptoms, the pathological load would be lower, increasing the chances of success of 
a disease modifying therapy [10]. Delaying the onset of AD by 5 years could lower the number of 
patients with AD by a third in 2050, reduce the number of patients with severe dementia, ensure 
patients spend longer with milder symptoms and a better quality of life and would reduce the 
socioeconomic burden by 36% [11].  
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An early diagnostic test could also be used to aid clinical trials by identifying patients most likely to 
benefit from the proposed treatment, which may increase the chances of a significant result. For 
example, the bapineuzumab [12, 13] and solanezumab [14] clinical trials in 2010 and 2014 were 
criticised as some participants might not have suffered from AD [12], might have been at different 
stages in the disease progression [13] and some might have suffered from mixed dementia [10]. A 
pre-screening step on the participants before the start of the trial to include those with only AD could 
have increased the significance of the trials. If mass screening on those over 65 could be implemented, 
AD could be diagnosed before symptoms became apparent. Therefore, a non-invasive, reliable 
method of detecting AD pre-symptomatically is needed to aid further treatment progression.  
Other benefits of early diagnosis include: reducing the uncertainty in patients regarding cause of 
symptoms, preventing doctors giving certain medications that can aggravate AD symptoms, allow the 
patient to prepare for the future and make decisions on care plans while being able to give consent 
and enable access to support services [15-18]. It has also been shown in a study of 970 patients that 
the shorter the interval between onset of symptoms and diagnosis, the longer the patients survived 
[19]. Early diagnosis is more cost-effective, as cost models based on early diagnosis and then providing 
aid or drug treatments using donepezil found savings are largely due to reduced time in care homes 
[20, 21].  
There are however ethical implications in early diagnosis of AD, mainly surrounding the benefit for the 
individual considering there is currently no disease modifying therapy, the social stigma attached to a 
dementia diagnosis, the effects on the patient once the diagnosis has been given, including: risk of 
suicide, increased insurance premiums or questions on whether the patient should hold a driving 
licence [16, 22, 23]. There is also the side-effects of mis-diagnosing AD with a treatable disease and of 
a false positive diagnosis where treatments could cause harm and increase expense [16, 22, 24].  
To diagnose AD before the presence of symptoms mass screening would need to be implemented, 
logistically the most relevant diagnostic technique would be biomarker detection in peripheral blood. 
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Currently there are advances in the detection of molecular biomarkers in the peripheral blood of AD 
patients, for example amyloid-β ratio’s in plasma have been found to correspond to the amyloid-β 
burden in the brain [25].  
1.2 Aims of the Thesis 
The theme of the thesis was to determine the feasibility of micro-ribonucleic acid (miRNA) as early 
biomarker of AD in the peripheral blood, the thesis had three aims: 
• To analyse miRNA changes in the post mortem brain of AD patients. It was hypothesised that 
the pathological miRNA changes seen in the brain could be reflected in the peripheral blood, 
and therefore finding the miRNAs the correlate with the progression of AD could be used to 
identify early deregulated miRNA suitable for biomarker diagnosis.  
• To determine if deregulated miRNA found in the brain are linked to one of the early 
pathological changes in AD, qne of which is the activation of astrocytes,. It was hypothesised 
that the early deregulated miRNA would have an impact on the disease progression. 
Therefore, finding the role these miRNAs have could give insight into their impact on AD 
progression and if they could be used as a therapeutic target.  
• And finally, to investigate the feasibility of using a quartz crystal microbalance (QCM) to detect 
changes in miRNA levels in the peripheral blood.  
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1.3 Organisation of the Thesis 
From the aims outlined the thesis was divided into 5 chapters. Chapter 2 is an overview of the 
literature outlining the pathology of AD, diagnostic techniques and miRNA detection methods. 
Chapter 3 uses the polymerase chain reaction (PCR) to determine relative levels of miRNA in the 
post-mortem brain through the progression of AD. Chapter 4 looks at activating an astrocytoma cell 
line using lipopolysaccharides (LPS) and tumour necrosis factor (TNF-α), over-expressing the 
astrocytes with miRNA, then analysing the concentration of metabolites, cytokines and growth factors 
in the cell supernatant. Chapter 5 determines the feasibility of using QCM to detect miRNA by using 
single stranded deoxyribonucleic acid (ssDNA) as a model system. Finally, Chapter 6 outlines the 
contribution of the thesis, limitations in the conclusions and future work.  
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Chapter 2: 
Literature Review 
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2.1 Introduction 
The following chapter aimed to describe the pathology of AD which was split into 4 areas: the build-up 
of both amyloid-β and tau in the brain, chronic neuroinflammation and neuronal loss. The chapter 
then moves on to an overview of current AD diagnostic techniques and into AD diagnosis using 
biomarkers in physiological fluid. Finally, the detection systems used to quantify these biomarkers. A 
systematic review was also conducted which extracted all articles looking at the deregulation of 
miRNA in the blood of AD patients.  
2.2 Alzheimer’s Disease 
Alzheimer’s Disease (AD) is a slow progressing disease with three phases: a long prodromal stage 
followed by mild cognitive impairment (MCI) and then late AD. Early symptoms of AD are 
characterised by difficulty in remembering recent conversations, names or events and evidence of 
apathy and depression. Other symptoms then develop including impaired communication, 
disorientation, confusion, poor judgement and behaviour changes, ultimately leading to difficulty in 
speaking, swallowing and walking [26].  
Pathology is characterised by the build-up of insoluble extracellular sticky deposits of amyloid-β 
protein, which accumulate mainly around neurons (amyloid-β plaques), and a hyper-phosphorylated 
microtubule associated protein (tau) in the brain along with neuroinflammation and neuronal loss 
[27]. Amyloid-β was first isolated in 1985 from patients with AD and Down’s Syndrome [28], as those 
with Down’s Syndrome have increased risk of dementia (due to extra chromosome 21 which contains 
the gene encoding for APP [29]), and is produced from cleavage of the amyloid precursor protein (APP) 
by β-secretase also referred to as BACE1 (Beta-site APP cleaving enzyme 1) followed by ɣ-secretase 
[30] as outlined in Figure 1. APP in a healthy brain is involved in cellular homeostasis, for example, 
controlling cholesterol, delivery of vesicle carriers, cellular growth and proliferation [31]. Amyloid-β is 
proposed to be part of lipid homeostasis [32] and an antimicrobial peptide [33].  
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Figure 1: Schematic showing APP processing to produce amyloid-β   
 
Tau stimulates the assembly of tubulin into microtubules, resulting in stabilisation of the microtubule 
network, which is part of the cell’s cytoskeleton [34]. The biological activity of tau is regulated by its 
phosphorylation; in AD tau becomes hyper-phosphorylated, 3-4 fold higher compared to a healthy 
control [35, 36]. The hyperphosphorylated form does not bind to tubulin and inhibits microtubule 
assembly [37] as shown in Figure 2. The site of phosphorylation controls tau’s capacity to inhibit 
microtubule assembly and its ability to self-aggregate into filaments [38-40].  
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2.2.1 Amyloid-β and Tau Staging 
In 1991, Braak and Braak mapped the distribution and spread of both amyloid-β and 
hyper-phosphorylated tau in the brain during the progression of AD [27]. For amyloid-β Braak 
determined that deposits are mainly found in the isocortex of the cerebral cortex of the brain. That 
the amyloid-β plaques are not uniform in shape or size and early stage accumulation is inconsistent, 
suffering from inter-individual variation. Amyloid-β deposition also develops before the onset of tau, 
however, the presence of amyloid-β does not necessarily mean tau pathology will develop [27]. Braak 
and Braak developed a three-stage progression of amyloid-β in AD. During stage A, amyloid-β is found 
in the base layer of the frontal, temporal and occipital lobes. In stage B, amyloid-β progresses to almost 
all isocortex areas and in stage C, amyloid-β is densely packed in the isocortex [27].  
Figure 2: Microtubule destabilisation due to 
hyper-phosphorylated Tau. 
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Other researchers developed pathological scales for amyloid-β including: the 5 phases by Thal et al 
[41] in 2002 using post-mortem brain tissue and 4 phases by Grothe et al [42] in 2017 using 
neuroimaging. The amyloid-β phases developed by Thal et al [41] are shown in Figure 3. showing initial 
amyloid accumulation starts in the neocortex then spreads to other parts of the brain, a more 
extensive distribution of amyloid when compared to the three Braak stages. Grothe et al supports the 
Thal phases, especially phases 1-3, when they used neuroimaging to determine the spread of 
amyloid-β. They conclude that the amyloid-β deposition follows a predictable pattern, however their 
research does not indicate whether the participants in the study will inevitably progress through the 
stages or the time in which this progression would occur [42].    
 
Figure 3: Schematic diagram showing the staging of amyloid-β deposition developed by Thal et al. 
The Braak stages (Figure 4) correspond to the distribution and spread of tau through the brain during 
AD progression. Braak stages I and II are centred on the transentorhenial region, with stage II being 
more densely packed than stage I with tau pathology. When progressing to stage III, pathology moves 
into the entorhinal region with low levels of tau seen in CA1 of the hippocampus and mild or negligible 
changes present in the isocortex [27]. Due to the hippocampus being responsible for episodic memory, 
damage here leads to a loss of memory connected to autobiographical events [43] and corresponds 
with early symptoms seen in AD. At stage IV there is increased pathology in the entorhenial region 
and CA1 hippocampus. There is no detectable brain atrophy and the pathology does not meet criteria 
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for neuropathologic diagnosis of AD. At stage V, tau is found in almost all areas of the hippocampus 
and the isocortex, with all areas mentioned severely affected by stage VI. Involvement of the isocortex 
corresponds to late AD and clinical diagnosis [27]. It is estimated that it can take 48 years to develop 
from Braak stage I to Braak stage V in which AD symptoms are apparent [9]. A large proportion of that 
time is when the disease is non-symptomatic because it can take 30 years to progress from stage I to 
stage III [9]. There are limitations to staging disease progression, for example it is difficult to get a 
representative sample of the population which includes all socio-economic groups and races, and in 
the assumption that all patients with AD will follow one pattern of pathology, so don’t allow for 
patients that may follow another distinct pattern, or for patients with mixed dementia pathology [44].  
 
Figure 4: Schematic showing the movement of amyloid-β plaques and tau during the Progression of AD 
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 2.2.1.1 Amyloid and Tau in Normal Aging 
Evidence suggests that 30% to 50% of people between 57 and 102 who are non-symptomatic at 
autopsy show AD pathology in the brain [45, 46]. The AD pathology could be due to normal aging [47, 
48] or the patients have pre-clinical AD [46, 49, 50]. Large studies conducted on the presence of AD 
pathology found that Braak stage correlates with dementia progression and those who are cognitively 
normal with severe dementia accounted for between 8% -12% of participants [51-53]. It has been 
suggested that these individuals with AD pathology and no cognitive symptoms have a cognitive 
reserve. This reserve allows them to withstand the effects of AD pathology [54, 55]. However, it has 
also been found that an individual with AD pathology at autopsy can be classed as clinically normal 
during testing, but they do show significant differences in some aspects of cognition when compared 
to individuals with no AD pathology [55, 56]. This could support the hypothesis that the AD pathology 
in non-demented patients is due to normal aging. Another aspect that could support this is that 
20%-30% of cognitively normal adults have amyloid-β deposition in the brain [57-59] and abnormal 
amyloid-β can be found without the presence of tau pathology [60]. However, contradictory to this, 
Tsartsalis et al has shown that low levels of tau can be present without amyloid-β deposition [61].  
2.2.2 Neuroinflammation 
The build-up of aggregated proteins in the brain can lead to neuroinflammation [62, 63]. Migratory 
cells known as microglia are distributed throughout the brain. They sense pathogens using their 
ramified process that scan the brain for insults [64]. It has been hypothesised that an initial insult, for 
example amyloid-β or a strong infection, activates microglia. The activated microglia secrete various 
cytokines and chemokines which in turn attract more microglia and astrocytes. In a healthy brain, the 
astrocytes and microglia remove the initial stimulus then deactivate the inflammatory response and 
reinstate homeostasis. In AD, the recruited microglia and astrocytes fail to remove the stimulus 
leading to constant cytokine and chemokine production [65, 66]. 
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2.2.2.1 Normal astrocyte function 
Astrocytes have five to eight major processes which ramify into fine appendages [67]. The terminal 
processes, called end feet, contact blood vessels, synapses, myelin sheaths, oligodendrocytes, 
microglia and neighbouring astrocytes through gap junctions (mainly composed of proteins called 
connexins [68]) and each astrocyte is highly organised into a specific spatial territory [69]. In the 
human cortex, an individual astrocyte’s territory can contain between 250,000 and 2 million neuronal 
synapses [70]. 
There is a heterogeneity in astrocytes with around 11 phenotypes [71], although they can be classified 
into two distinct groups: protoplasmic astrocytes in the grey matter, which are attributed to neurons 
and synapses, and fibrous astrocytes in the white matter associated with nodes of Ranvier and 
oligodendroglia [72]. Astrocytes play important roles in: synaptic homeostasis, synaptic function, 
regulation of blood flow, energy metabolism and the blood brain barrier (BBB) [71]. They can regulate 
potassium, sodium, calcium and water to maintain homeostasis [73, 74].  
Astrocytes are involved in synaptic activity since neurotransmitters, such as glutamate, noradrenaline 
and acetylcholine can bind to receptors on astrocytes. This causes an increase in calcium ions, the 
magnitude of which is dependent on the levels of neurotransmitter [75, 76]. The calcium ions can then 
either stay in the astrocyte processes, which allows signals from different synapses to be isolated, or 
propagate across the cell [77]. Astrocytes then secrete gilotransmitters like adenosine triphosphate 
(ATP), glutamate and D-serine to regulate activity of neural receptors [78-82]. This enables astrocytes 
to both sense and modulate the flow between pre-synaptic neurons and post-synaptic neurons [83].  
Neurotransmitters like glutamate, gamma-aminobutyric acid (GABA) and glycine can be taken up by 
astrocytes to remove them from the synaptic space. For example, glutamate is absorbed by the 
astrocytes then glutamine synthase is used to convert glutamate into glutamine, the glutamine is then 
reconverted by synapses into glutamate. This prevents detrimental accumulation of glutamate [84, 
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85]. Astrocytes are also involved in the elimination of synapses through phagocytosis receptors 
MEG10 and MERT [86], or by attracting microglia to synapses through the complement pathway [87]. 
In response to synaptic activity, astrocytes can alter the diameter of arterioles through their direct 
contact with both synapses and blood vessels [88, 89]. This is achieved through an increase in 
glutamate from neurons, which then induces a calcium ion increase in astrocyte end feet. This triggers 
the release of either 20-hydroxyeicosatetraenoic acid (20-HETE) or prostaglandin E2 (PEG-2), which 
can act on smooth muscle cells to change the diameter of arterioles [90, 91]. Astrocytes can both 
dilate and constrict arterioles depending on the partial pressure of oxygen in the brain [92]. In high 
oxygen conditions, the increase in calcium ions causes the release of 20-HETE, resulting in 
vasoconstriction [90]. Vasodilation is controlled by the release of PEG-2 at low oxygen levels [93]. An 
astrocyte’s proximity to blood vessels means they can take up glucose and are the principal storage 
site for glycogen. Glycogen stores can be modulated by transmitters such as glutamate and broken 
down into lactate to be used as an energy substrate for neurons during low glucose concentrations 
[94, 95].   
Astrocytes are also responsible for the secretion of various growth factors, for example: fibroblast 
growth factor (FGF) [96] and nerve growth factor (NGF) [97]. FGF promotes survival of hippocampal 
neurons [98] and NGF regulates survival and differentiation of sensory and sympathetic neurons [99]. 
However, NGF has also been found to induce cell cycle arrest [100] and reduce the number of 
hippocampal astrocytes [101].  
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Figure 5: Schematic illustrating an astrocyte’s a) effect of vasodilation and vasoconstriction of blood 
vessels, b) glutamate and glutamine processing and c) glucose and lactate processing. 
 
Evidence shows that astrocytes are involved in maintenance of the BBB. The BBB is a term used to 
describe the blood vessels in the central nervous system, as they have properties which allow the 
control of molecules, ions and cells between the blood and central nervous system [102]. This is mainly 
comprised of endothelial cells held together with tight junctions [102]. In vitro, astrocytes can induce 
barrier properties in endothelial cells, leading to tighter tight junctions between the cells [71, 103]. 
Other studies suggest a role for astrocytes in regulating BBB properties in cerebral epithelial cells, 
through bone morphogenetic protein signalling mechanisms on astrocyte endfeet which, when 
disrupted, can cause leaks [104]. 
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2.2.2.2 Astrocytes in Alzheimer’s Disease 
During AD progression, there is an increased number of activated astrocytes, which accumulate before 
the presence of amyloid-β plaques and hyper-phosphorylated tau [105-107]. In late AD, the activated 
astrocytes are mainly associated with amyloid-β plaques [108, 109]. Activated astrocytes are marked 
by an upregulation in Glial Fibrillary Acidic Protein (GFAP) [110] and vimentin [111], a ramified 
phenotype, increased proliferation, excitotoxic glutamate release, inflammatory cytokine production, 
BBB breakdown and amyloid-β production [76, 112-114]. The upregulation of GFAP correlates with 
Braak stage progression [70, 115]. GFAP is used as a marker for astrocytes and is contained in the 
intermediate filament. However, GFAP is not contained in the finer processes; not all astrocytes are 
GFAP positive and not all GFAP positive cells are astrocytes [116, 117].  
Reduced astrocyte volume and surface area have also been associated with AD [118-120]. 
Observations in mice have shown atrophy of astrocytes, characterised as a reduction in distal 
processes, before signs of AD pathology. This occurs in the endorhinial cortex in mice at 1 month and 
the hippocampus at 9 months [119] and is supported by the dysregulation of actin cytoskeleton genes 
early in AD [121].  
Exposure of astrocytes to amyloid-β has been found to induce activation [122], express inflammatory 
markers [62] and lead to abnormal calcium transits [123]. Amyloid-β is mainly produced by neurons, 
however, astrocytes have been found to express BACE1 (β-secretase-1) in response to chronic stress, 
or when in close proximity to amyloid-β plaques [124, 125], and therefore can produce amyloid-β 
[126]. Amyloid-β clearance is facilitated by astrocytes through movement into the Cerebrospinal Fluid 
(CSF) by aquaporin-4 (AQP4) water channels [127], loss of perivascular AQP4 localisation on astrocytes 
has been associated with increasing Braak stage [128]. Clearance can also occur by uptake into cells 
through CD36, CD47 and receptor for advanced glycation end products (RAGE receptors) [129, 130], 
by apolipoprotein E lipidation [131] or through proteases like matrix metalloproteinase-2 (MMP-2) 
and matrix metalloproteinase-9 (MMP-9), which are upregulated in astrocytes surrounding amyloid-β 
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plaques [132]. Astrocytes can phagocytose amyloid-β and retain the protein to form large toxic 
intracellular deposits [41, 130, 133], which, after death, can lead to secondary plaques [134].  
Amyloid-β influences astrocytes’ synaptic support as it can cause sporadic calcium signalling [123]. 
The changes in released calcium can cause additional oxidative stress and mitochondrial dysfunction 
by activation of NADPH oxidase (nicotinamide adenine dinucleotide phosphate-oxidase), which results 
in reduced antioxidant support, leading to neuronal death [135, 136]. Amyloid-β can also affect 
astrocyte metabolism by increasing glucose uptake and its incorporation into glycogen, glycolysis and 
lactate release [112]. These changes in metabolism can decrease neuronal viability through increased 
oxidative stress, for example hydrogen peroxide [112], which is known to induce neuronal death [137]. 
However, there is conflicting evidence as results with cultured astrocytes show amyloid-β may also 
inhibit glucose uptake [138].  
Increased glutamate has been found in response to amyloid-β and deregulation of glutamate 
receptors [139, 140], receptors such as: vesicular glutamate transporter 1 (VGLUT1), 
glutamate/aspartate transporter (GLAST), glutamate transporter 1 (GLT1) and excitatory amino acid 
carrier 1 (EAAC1) [115, 141-143], along with a decrease in glutamine synthase [144, 145]. The 
glutamate receptor deregulation leads to a decrease in glutamate transporter activity [146] and an 
accumulation of neurotoxic glutamate, resulting in oxidative damage by reactive oxygen species and 
lipid peroxidation products [147].  
There is limited but increasing literature on the effect of hyper-phosphorylated tau on astrocytes in 
comparison to the effect of amyloid-β [148, 149]. One example shows that overexpression of tau in 
cell culture models can cause a decrease in stable detyrosinated microtubules, which leads to collapse 
of the intermediate filament network, fragmentation of the Golgi apparatus, atrophy and 
non-apoptotic death of astrocytes [150].  
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2.2.3 Neuronal Loss 
There is a significant decrease in the number of neurons in AD patients [151-153]. A decrease in 
neuronal density occurs in the hippocampus, entorhinal cortex, amygdala, nucleus basalis of meynert 
and nucleus basalis [152-160]. This neuronal loss has been linked to caspase-3 activation (an indicator 
of apoptosis) due to increases in intraneural amyloid-β [161]. 
2.3 Other Forms of Dementia 
AD is the most common type of dementia, other forms of dementia include vascular dementia (VD), 
dementia with lewy bodies (DLB) and frontotemporal dementia (FD).  
2.3.1 Vascular dementia 
VD is caused by damage to blood vessels in the brain which impair blood flow and therefore leads to 
reduced oxygen and nutrients needed for normal brain function. A diagnosis of probable VD would 
include symptoms such as gait disturbance, frequent falls, early urinary symptoms, personality and 
mood changes and subcortical deficits such as psychomotor retardation. For a diagnosis of definite VD 
there would need to be probable AD symptoms along with cerebrovascular disease and no evidence 
of amyloid plaques and hyperphosphorylated tau [162]. There are many different subtypes of VD, the 
types vary because of the cause, where the blood vessel damage is in the brain and the size of the 
damage. For example, multi infarct dementia is a subtype of VD caused by multiple large and small 
areas of blood vessel damage not localised in a specific area. In most cases this damage is due to 
atherosclerosis in large blood vessels [162].  
The progression of dementia in AD is different to that seen in VD. The onset of VD can be sudden 
depending on the subtype, although some can gradually present symptoms. The decline in function in 
VD is a non-linear stepwise decline, whereas AD is a gradual linear cognitive decline. VD also presents 
more motor impairments when compared with AD [163]. 
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2.3.2 Dementia with Lewy Bodies 
DLB is characterised by the presence of α-synuclein aggregates and ubiquitin in neurons called lewy 
bodies in the neocortex, forebrain and brainstem of the brain [164]. The presence of α-synuclein starts 
in the peripheral nervous system, then to the brain stem and up through the brain to the neocortex 
[165]. DLB patients experience fluctuations in cognitive impairment centred on attention and 
alertness, the fluctuations can be over minutes, hours or days [166]. The earliest symptoms are 
delirium and consciousness disorders then into psychiatric and behavioural impairments like visual 
hallucinations, parkinsonism and disturbed sleep [164, 166]. For a DLB diagnosis there needs to be 
fluctuations in attention and alertness, visual hallucinations, parkinsonism, frequent falls, other 
hallucinations and sleep disorders [166].  
DLB differs to AD as DLB present visuospatial disfunction and fluctuations in impairment. Patients with 
AD generally perform better on visuospatial testing and those with DLB perform better on verbal 
memory tests. Both forms of dementia are caused by aggregated protein in the brain however the 
spread of these aggregates through the brain are different. AD starts in the centre of the brain, the 
hippocampus, and spreads to the outside of the brain. For DLB the aggregates start from the brain 
stem and spread up to the top of the brain.  
2.3.3 Frontotemporal Dementia 
FD is a term that describes several neurodegenerative diseases caused by neuronal loss, gliosis and 
abnormal protein deposition in the frontal and temporal lobes [167]. FD is mainly associated with 
symptoms of abnormal behaviour or language [168-170]. There are three types of FD: the behavioural 
type and two focused on deficits in language, these are non-fluent variant primary progressive aphasia 
and semantic-variant progressive aphasia. As the disease progresses the patient may exhibit 
symptoms of all three FD types, this is due to disease pathology effecting a larger area of the brain in 
the later stages [168-170]. During the progression of the disease patients can experience cognitive 
impairment and motor deficits and in the later stages have difficulty eating and moving  [168-170]. 
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Symptoms of patients with behavioural type FD include personality changes, abnormal social 
behaviour or impulsive and careless actions [168-170]. Semantic variant primary progressive aphasia 
FD type in the early stages includes symptoms such as forgetting places and names of objects along 
with deficits in spelling and pronunciation [168-170]. The disease starts in the temporal lobe causing 
problems with language then as the disease spreads to the orbitofrontal lobe the patent exhibits 
behavioural changes such as irritability, insomnia and selective eating [168-170]. Non-fluent variant 
primary progressive aphasia causes altered speech as it becomes slow and inconsistent, they misuse 
grammar, have problems understanding complex sentences and patients can have mild anomia of 
verbs [168-170]. 
There is a heterogeneity in the pathological features of FD, however they can suffer from tau 
deposition in the brain, one of the characteristics of AD. FD patients progress quicker than AD  
(measured from onset of symptoms to death), and onset of FD is more common in those younger than 
65 whereas AD is more common in those over 65 [171]. In comparison to AD, FD exhibits more 
behavioural alterations in the early stage of the disease compared to memory deficits in AD.  
2.4 Diagnosis of Alzheimer’s Disease 
In 2011 the National Institute on Aging and the Alzheimer’s Disease Association developed a set of 
core clinical criteria for dementia outlined in Table 1. If a patient fit these criteria and there was a clear 
history of a slow decline in cognition which was more prominent in a patients: ability to learn and 
remember information, word finding ability, their spatial cognition or their reasoning, judgement and 
problem solving, then they are diagnosed with probable AD [172]. A diagnosis of possible AD can be 
given when the patient meets criteria for dementia, but symptoms had a sudden onset or there is 
insufficient evidence of a slow decline in symptoms [172]. An AD diagnosis cannot be given when 
patient:  has a history of stroke, presence of extensive infarcts or severe white matter hyperintensity 
burden, they display features of dementia with Lewy bodies or have evidence of other neurological 
disease [172].  
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AD has also been described as a biopsychosocial disorder. A biopsychosocial disorder is one that 
involves interactions between biological elements (genes or biochemical changes) and psychosocial 
elements (mood and personality) [173]. Biological elements are evidenced in the fact that increasing 
age [174] and the presence of the APOE ε4 gene is a risk factor for the development of AD [175] along 
with the accumulation and spread of abnormal amyloid-β and tau in the brain [27]. One psychosocial 
element risk factor includes low levels of education [176] or a low IQ score [177] and low levels of 
mental stimulation [178]. Psychosocial symptoms of AD can be seen in Table 1, for example difficulty 
in speech and changes in behaviour [172].  
A probable or possible AD diagnosis can be supported with biomarkers, the biomarkers mentioned 
are: atrophy of the brain, glucose metabolism in the brain and amyloid deposition which are all 
measured using neuroimaging, along with the concentration of amyloid and tau in the CSF [172]. 
However routine biomarker analysis was not recommended as there was no standardisation of 
analytical variables to measure biomarkers, access to the tests depended on the memory clinic 
patients were referred to, and that more research was needed to understand the clinical utility of the 
marker [172].  
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Table 1: Table detailing the core clinical criteria for AD diagnosis 
Core Clinical Criteria for Dementia: 
• When symptoms interfere with usual activities and ability to function at work 
• Exhibit a decline in functioning and performance which cannot be explained by delirium or 
psychiatric disorders 
• Diagnosed cognitive impairment through conversations with patient and family or cognitive 
assessment, for example the mini-mental state examination (MMSE). 
• Impairment in two or more of the following: 
o Acquire or remember new information (repetitive questions or conversations, 
misplacing personal belongings, forgetting events or appointments, getting lost on a 
familiar route 
o Reasoning and handling of complex tasks (poor understanding of safety risks, inability 
to manage finances, poor decision-making ability, inability to plan complex or 
sequential activities) 
o Visuospatial abilities (inability to recognize faces or common objects or to find objects 
in direct view despite good acuity, inability to operate simple implements, or orient 
clothing to the body) 
o Language, in speaking, reading or writing (difficulty thinking of common words while 
speaking, hesitations; speech, spelling, and writing errors) 
o Personality or behaviour (uncharacteristic mood fluctuations such as agitation, 
impaired motivation, initiative, apathy, loss of drive, social withdrawal, decreased 
interest in previous activities, loss of empathy, compulsive or obsessive behaviours, 
socially unacceptable behaviours) 
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2.4.1 Mini-Mental State Examination 
The MMSE can be used to asses cognitive impairment, assessment of cognition is one of the criteria 
outlined in Table 1. The MMSE was designed by Folstein in 1975. The test takes 5-10 min to complete 
and has a variety of questions with a total score of 30 [179]. An adult with no cognitive impairment 
will obtain a score of 23-30, those with mild cognitive impairment achieving 18-23 and below 17 
indicates those suffering from severe cognitive impairment and AD [180]. 
There have been numerous studies on the reliability, sensitivity and selectivity of the MMSE. The 
test-retest reliability for a time interval of 2 months or less was between 80-95%, with reliabilities 
found lower due to illness effects, for example those suffering from delirium [180]. Higher time 
intervals of 1 to 2 years show a 2 point change in MMSE for 42% of individuals [181]. The tests 
specificity and sensitivity suffer from floor and ceiling effects. The sensitivity of the MMSE is its ability 
to identify patients who are cognitively impaired. The sensitivity varies depending on the patients 
tested; for example, if patients are severely cognitively impaired, the sensitivity is high, on average 
85%, whereas for those with mild cognitive impairment the sensitivity is 20% [180, 182].  The 
sensitivity is affected by celling effects. This means the participant’s personal characteristics have a 
positive effect on the results, reducing the sensitivity [183]. The selectivity, i.e. whether the test can 
identify those who are cognitively intact, is between 46-100%. The variation is attributed to the 
education level of the participant; those with a low education level perform poorly on the test pushing 
them into MCI [180]. This educational bias is an example of a floor and ceiling effect, as an individual 
with poor education will result in a floor effect, and high education a celling effect [183, 184].  Floor 
effects are when the cognitive test is negatively affected by the participants personal characteristics, 
and impact the selectivity [183]. 
Other disadvantages include that fact that the MMSE was not specifically developed for diagnosing 
dementia and therefore questions pertaining to memory, one of the most common early domains to 
be affected equates to only 3 of the 30 points in the test [185]. The test requires the participant to be 
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literate as two of the questions involve reading and writing [185], in 2013 the UK 4.1% of the 
population aged 55-65 were illiterate [186].  There is a lack of standardisation in the testing procedure 
that effects the reliability of the test [185], and the MMSE diagnoses AD based on symptoms, therefore 
the test is unable to diagnose non-symptomatic AD.  
2.3.1 Biomarkers 
A possible or probable diagnosis of AD can be supported with biomarkers. A biomarker can be defined 
as ‘a characteristic that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes or pharmacologic responses to a therapeutic intervention’ [187]. 
There are various types of biomarkers including: prognostic biomarkers that predict survival, 
predictive biomarkers that identify patients who are more likely to benefit from a therapy and 
surrogate biomarkers that predict the outcome after a therapy [188]. Biomarkers in physiological fluid 
influence up to 70% of clinical medical decisions [189]. 
AD biomarkers could be used to identify adults at risk of developing AD or assist in AD diagnosis. A 
biomarker could also identify MCI patients that will develop into AD or any other form of dementia. 
The biomarker could correlate with the progression of the disease, so isolate AD patients that 
deteriorate faster or finally, those who will benefit the most from a proposed treatment in a clinical 
trial. There are various factors that define the utility of a biomarker including: the sensitivity, specificity 
and ease of use. For example a biomarker to determine an individual at risk of developing AD would 
have a lower threshold for sensitivity and specificity when compared to a diagnostic biomarker [190].  
The sensitivity and specificity of a biomarker is important. A high specificity means a biomarker can 
identify those who are cognitively normal and therefore minimise false positives. A high sensitivity will 
lead to the identification of a high percentage of AD patients and reduce the number of false negatives.  
The National Institute on Aging and the Alzheimer’s Disease Association developed criteria that an AD 
diagnostic biomarker needs to meet [191, 192], these are: 
• Specificity above 85% (able to identify healthy adults and distinguish from other dementia’s) 
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• Sensitivity above 85% (able to identify all patients suffering from AD) 
• Prior probability (tested the prevalence of the disease in the patient cohort used) 
• Positive predictive value of 80% (those the biomarker tested positive have been diagnosed 
with AD at autopsy) 
• Negative predictive value of 80% (those the biomarker tested negative have not been 
diagnosed with AD at autopsy)  
• Validated in neuropathologically confirmed cases 
• Reliable, reproducible, non-invasive, simple to perform, allow for repeated measurements 
over time, samples should be stable and inexpensive.  
• The data should be published in peer-reviewed journals and be reproduced by at least two 
independent researchers 
 
2.3.2 Biomarkers for AD 
The biomarkers mentioned in the diagnosis of probable AD included the neuroimaging techniques 
Positron Emission Tomography (PET) to determine amyloid deposition or glucose metabolism and 
magnetic resonance imaging (MRI) to measure brain atrophy along with levels of amyloid-β and tau 
in the CSF [172]. The occurrence of abnormal amyloid deposition and in PET scans can precede the 
onset of symptoms [193]. A large meta-analysis has found that results from amyloid-β PET brain 
imaging correlated with dementia diagnosis [194], and has the ability to differentiate between 
Parkinson’s and the different dementia types due to metabolism patterns [195, 196]. For early 
diagnosis, the conversion of MCI to AD, PET has been found to have a sensitivity of 94%, however the 
specificity depends on the follow up time period and can vary between 51-74% with increasing time 
[197]. There is evidence that 30-40% of cognitively normal adults can have significant amyloid 
deposition [57-59], this combined with evidence showing amyloid deposition can occur up to 20 years 
before onset of symptoms [198], means cognitively normal adults showing positive results for amyloid 
deposition could be a risk factor for developing AD.  
Another PET imaging biomarker is glucose metabolism in the AD brain. The AD brain shows a reduction 
in brain glucose metabolism which can occur before development of symptoms [199, 200]. The 
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metabolism Is able to correctly diagnose 95% of AD patients, and distinguish between AD patients and 
those suffering from dementia with lewy bodies, frontotemporal dementia and healthy controls in a 
multicentre study [201, 202].  
The third neuroimaging biomarker is atrophy of the brain which can be measured using MRI. Atrophy 
of the brain occurs in the medial temporal lobe, especially in the hippocampus and entorhinal cortex 
[203]. The literature shows that after increased amyloid deposition in the brain it is followed by 
abnormal atrophy measurements [204], this is supported with evidence that cognitively normal adults 
with a positive amyloid deposition PET scan show normal brain MRI scans [205]. Hippocampus atrophy 
measurements by means of MRI show sensitivities for diagnosis of AD between 80-90%. However 
hippocampal atrophy is also present in both frontotemporal and vascular dementia [206]. For this 
reason, in 2001, the method was not recommended for use by the American Academy of Neurology 
[207]. Although studies have since found significant differences between hippocampus atrophy in AD 
compared with dementia with lewy bodies and vascular dementia, with a sensitivity of 90% and 
specificity of 94% [208]. 
The final AD biomarker was measurements of Amyloid-β 42, total tau and phosphorylated tau in the 
CSF [172]. Detection of proteins in CSF requires an invasive lumbar puncture procedure under local 
anaesthetic with common side effects including mild to moderate headache in 46% of cases [209-211]. 
The deregulation of the three proteins have been confirmed in several large multicentre studies and 
can identify MCI patients that will develop into AD [212-215]. The test’s sensitivity ranges between 
68% - 95% and specificity between 83% - 97% [216-220]. To quantify levels of amyloid-β and tau, 
studies used commercially available enzyme linked immunosorbent assay (ELISA) kits, the multi-centre 
studies conducted using the kits have resulted in a large variability in results [221], with the variation 
being too high to establish international cut-off values [222]. To combat this the AD association quality 
control programme for CSF biomarkers was launched, after standardisation and training the variation 
27 
 
was still high, between 15-25% [222]. Although, the CSF test has been used in memory clinics, with 
researchers finding that the CSF test altered a patients diagnosis in only 7% of cases [223].  
2.3.3 Alzheimer’s Disease Progression and Biomarkers  
The four biomarkers MRI atrophy, PET glucose metabolism, PET amyloid deposition and Amyloid-β, 
total tau and phosphorylated tau in the CSF were compared against the biomarker criteria outlined in 
section 2.3.1. Table 2 shows that the four biomarkers do not comply with all the biomarker criteria. 
One reason for this is the large variation in the neuroimaging and CSF tests sensitivity and specificity.  
Jack et al developed a model that linked the 4 AD biomarkers to the progression of AD symptoms 
(Figure 6) [193]. It shows that the altered biomarker levels all occur before the onset of symptoms, 
which is supported in the literature [193, 224] and that cognitive decline correlates with the 
abnormality in the biomarkers [193]. The literature shows that the levels of tau in the CSF do not 
correlate with cognitive decline [225], brain atrophy MRI does correlate with cognitive decline [226] 
and glucose metabolism also correlates with cognitive function [227]. Therefore, only two of the 
factors support the biomarker model developed by Jack et al [193]. In 2018 a symptomatic staging 
system was developed which is described in Table 3 [228]. The model developed by Jack et al [193] 
was the combined with the 2018 symptomatic stages to define the progression in the disease, this is 
also shown in Table 3..   
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Table 2: Table comparing the 4 biomarkers MRI atrophy, PET glucose metabolism, PET amyloid deposition and 
Amyloid-β 42, total tau and phosphorylated tau in the CSF to biomarker criteria 
*inter-rater reliability tested using Cohen’s kappa, **Information obtained from NICE guidelines, 
***Not present on NICE guidelines for the diagnosis of AD, **** Data obtained from clinical 
trials.gov website. 
 
Biomarker Criteria 
Biomarkers for AD  
Neuroimaging CSF 
Amyloid PET 
PET Glucose 
Metabolism 
Atrophy using MRI Aβ, t-tau & p-tau 
Specificity above 
85% 
42-74% [197, 229, 
230] 
42-89% [229-231] 90-97% [208, 232] 
83% - 97% 
[216-220]. 
Sensitivity above 
85% 
94-96% [197, 229, 
230] 
70-93% [229-231] 47-93% [208, 232] 
68% - 95% 
[216-220]. 
Prior probability     
Positive predictive 
value of 80% 
57-88% [229, 230, 
233] 
41-75% [229-231] 75-95% [232] 89-95% [234] 
Negative predictive 
value of 80% 
82-100% [229, 230, 
233] 
78-96% [229-231] 78-97% [232] 55-100% [234] 
Validated in 
neuropathologically 
confirmed cases 
Y [235, 236] Y [237] Y [238] Y [239] 
Reliable κ= 0.79* [229] κ= 0.55* [229] Y [238] 
Intra & inter 
assay reliability 
CV <15% [240] 
reproducible Y [241] Y [242] Y [243] N [222] 
non-invasive Y [244] Y [245] Y [238] N [209-211] 
simple to perform N N N [238] N 
Allow for repeated 
measurements 
Y Y Y Y 
Samples are stable N/A N/A N/A  
In-expensive £900 [246] £900 [246] £150 [238, 247] £450 [246] 
Published in a 
peer-reviewed 
journal 
Y[235] Y [199] Y [208] Y [216] 
Reproduced by at 
least two 
independent 
researchers 
Y [197] Y [201, 248] Y [249, 250] Y [216-220] 
Used by 
Clinicians** 
N*** Y [251] N*** Y [251] 
Used in Clinical 
Trials as an 
outcome measure 
Y [252] Y [253] Y [254] Y [255] 
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Figure 6: Schematic describing the change in AD biomarkers through the progression of the disease, taken from Jack et al.  
2013 [193]. 
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2.3.4 Other biomarkers in the literature 
The amyloid-β and glucose metabolism PET imaging, atrophy MRI measurements and amyloid-β/tau 
protein levels in the CSF biomarkers were mentioned in the 2011 diagnostic criteria. However, there 
are other biomarkers being investigated in the literature. The investigation of biomarkers in AD 
patients in the literature are reported for neuroimaging [226, 247, 253, 256], molecules in the CSF 
[215, 216, 219, 234, 239, 257, 258] and molecules in peripheral blood [259-265]. Other biological 
samples such as urine [266], breath [267] and saliva [268, 269] have potential for biomarker detection. 
More recently reported diagnostic tests include retinal imaging of amyloid-β [270], structural changes 
in the retina [271], and alterations in an AD patients sense of smell [272]  
2.3.4.1 Protein Biomarkers in CSF 
The most well-known biomarker for AD in the CSF is amyloid-β/tau protein levels, however another 
example is neurogranin. High levels of neurogranin in the CSF is a marker for loss of neurones and 
synaptic dysfunction, this is supported by the fact that the protein correlates with MRI atrophy 
measurements and can be seen in early stages of AD [273-275]. This is useful as synaptic loss correlates 
with cognitive impairment [273-275]. Several studies have also found that neurogranin can detect MCI 
patients that will progress to AD [276-279] and that neurogranin can differentiate AD from other forms 
of dementia [280]. Finally, neurogranin has been found to differentiate amyloid positive and amyloid 
negative PET scans with an accuracy of 71%, sensitivity of 79% and specificity of 60% [281]. An AD 
biomarker needs to have a sensitivity and specificity higher than 85% as outlined in section 2.3.1, 
therefore neurogranin cannot be used to identify individuals with positive or negative amyloid PET 
scans.   
2.3.4.2 Protein Biomarkers in Peripheral Blood  
Due to the invasive nature of obtaining CSF and the potential side-effects, the presence of AD 
peripheral blood biomarkers has been investigated. The presence of AD markers in blood is supported 
by the fact that 500 ml of CSF can be absorbed into the blood daily, and there is evidence of disruption 
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to the BBB during AD [282]. As some studies show increased permeability in microvessels surrounded 
by amyloid-β plaques [283] and elevated prothrombin levels in the prefrontal cortex which increases 
with increasing Braak stage [282]. Neuroimaging has also found significantly higher BBB leakage rates 
and BBB impairment in AD which correlates with MMSE scores [284, 285]. Although, in contrast, no 
change in BBB when comparing AD and aged controls is also reported [286-291], and there is an age 
dependant breakdown of the BBB in the hippocampus with some hippocampal areas worsening with 
MCI [292]. Impairment to the BBB during AD is supported by evidence showing that tight junction 
proteins in endothelial cells can be degraded by MMP-2 and MMP-9 leading to a leaky BBB [293]. 
There is an increased expression of both MMP-2 and MMP-9 in astrocytes surrounding amyloid-β 
plaques [132] and MMP-9 increases in stimulated astrocytes [294]. 
Amyloid-β is present in the peripheral blood and if the amount of amyloid-β 40 is equal to or above 
42 pg/ml, it will discriminate AD from a control with a sensitivity of 80% and specificity of 69% [295]. 
Amyloid-β levels also increase with age [296] and the diagnostic capability of amyloid-β in peripheral 
blood is not specific or sensitive enough for diagnosis of sporadic AD or MCI [297]. Although recent 
longitudinal studies have shown that high amyloid- β (1-42) in plasma can be used as a risk factor for 
developing AD, and therefore some utility as a screening biomarker [298]. 
An alternative to amyloid-β is the concentration of APP in platelets. In the late 1990’s three forms of 
APP were discovered with three different molecular weights 130, 110 and 106 kDa. It was found that 
AD patients had a lower ratio between the upper and lower forms of APP when compared to both 
aged matched controls and other types of dementia. AD patients had a ratio around 0.35 and the 
control groups greater than 0.83 with an accuracy of 74%, sensitivity of 75-88% and specificity of 
75-89% [299, 300]. Concentrations of APP decrease early only in the patients which progress from MCI 
to AD, with a sensitivity of 83% and specificity of 71% over a period of 2 years [300, 301]. A reduced 
APP ratio in platelets has been found in more than one peer reviewed journal [299, 300], however 
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sensitivity and specificity measurements are lower than the 85% cut-off and if a patient is on specific 
medication it can alter the APP ratio [300, 301].  
Recently the combination of APP669–711/amyloid-β 1–42 and amyloid-β 1–40/ amyloid-β 1–42 ratios 
have been found to accurately predict the amyloid-β burden in the brain with an accuracy of 90%, 
sensitivity >80% and specificity >81%, when compared to neuroimaging [25]. Currently this 
combination of biomarkers has only been found in one peer reviewed journal, and sensitivity and 
specificity values are just below the 85% cut-off. However, amyloid-β does develop early in AD, 
highlighting its usefulness an early diagnostic test, especially for clinical trials looking at altering the 
amyloid-β burden in the brain. Although, the presence of amyloid-β does not necessarily mean tau 
pathology will develop [27], and research has found that 20%-30% of cognitively normal adults have 
amyloid-β deposition in the brain [57].  
Other proteins tested are the levels of neurofilament light which has been found to increase in 
patients with MCI and AD when compared to healthy controls. The increase also correlates with CSF 
neurofilament light levels and brain atrophy attributed to AD [302]. Although care needs to be taken 
when using neurofilament as a biomarker because increased levels in blood can be found in other 
diseases such as frontotemporal dementia [303]. Additional proteins are triggering receptor expressed 
on myeloid cells 2 (TREM 2); concentrations in blood have been found to correlate with MMSE scores, 
however its ability to diagnose early is unknown [304]. BACE1 protein can differentiate AD from 
normal controls however BACE1 concentrations did not correlate with MMSE scores [305]. Gelsolin 
concentration in peripheral blood can determine normal controls from rapidly declining and slowly 
declining AD patients and concentrations correlate with progression scores using MMSE, there is 
however no significant difference between AD and normal controls in the brain [260]. All these 
biomarkers have not been assessed for feasibility in longitudinal studies with large numbers of 
participants. In conclusion, the literature shows no single protein biomarker which multiple 
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researchers have found to be a viable option for diagnosis of AD that fits all the requirements in 
section 2.3.2.    
Alternatives to using a single protein for AD diagnosis are the use of protein panels. Hye et al found 
10 proteins in the blood that have a strong association with the conversion of the prodromal disease 
to dementia, the panel had an accuracy of 87%, sensitivity 85%, and specificity 88% [306]. A panel of 
17 protein biomarkers in plasma was found to diagnose AD and correlate with the MMSE scores, with  
a sensitivity and specificity of 93%, however its ability to diagnose at an early stage is unknown [264]. 
Sattleker et al found a panel of 13 proteins in blood, with each protein corresponding to an aspect of 
AD pathology, for example fetuin B was related to left entorhinal atrophy [307]. The following review 
by Shi et al [308] outlines the current position of protein biomarkers in more detail along with its 
challenges. 
2.3.4.3 mRNA in Peripheral Blood 
There is evidence in the literature of using messenger-ribonucleic acid (mRNA) in the peripheral blood 
to diagnose AD. A systematic search of the literature was conducted using PubMed, web of science 
and google scholar. The following terms were used to find relevant studies “Alzheimer”, “mRNA” 
“peripheral blood” and “biomarker”.  From the literature search 11 mRNA were found, these are 
shown in Table 4 [261, 263, 304, 309-317]. Out of the 11 mRNAs found, only 1 mRNA had been 
replicated in more than one peer-reviewed journal, this was TREM2. TREM2 showed higher levels of 
mRNA in peripheral blood. None of the studies found had sensitivity or specificity values for using 
mRNA to diagnose AD [304, 310, 311]. 
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Table 4: Table to show the mRNA in the literature found to diagnose AD 
 
2.3.4.4 miRNA as Biomarkers for Alzheimer’s Disease 
miRNAs are small non-coding RNA, normally 22-23 nucleotides, that control gene expression by 
binding to the 3’-untranslated region (UTR) in mRNA. Through this, they suppress translation or induce 
degradation of the target mRNA [319]. There are over 2000 miRNAs in the human genome that 
regulate one third of the genes [320, 321], with 550 miRNA being expressed in the brain [320], 540 in 
peripheral blood mononuclear cells (BMC) [322] and 267 in serum [322].   
miRNAs are transcribed by ribonucleic acid (RNA) polymerase II/III in the nucleus to large RNA 
precursors called pri-miRNA. The pri-miRNA is processed by RNase III enzyme Drosha to be 
approximately 70 nucleotides in a hairpin structure. The pri-miRNA is then exported to the cytoplasm 
by exportin 5. After subsequent processing by the RNase III enzyme Dicer it releases a small RNA 
duplex which is then loaded into an Argonaute (Ago) protein. The mature miRNA then directs the 
Ago-miRNA complex to the target messenger RNA (mRNA) [319, 321, 323]. miRNA are secreted from 
cells through: the ago-miRNA complex [324, 325], high density lipoproteins [326], exosomes [327], 
microvesicles [328] or apoptotic bodies [329]. The miRNA complexes are stable in body fluids, and 
mRNA Biomarkers REF Change Blood Component 
Clusterin [261] higher Whole blood 
CCL5 [263] lower plasma 
Calreticulin [309] lower serum 
TREM2 [304, 310, 311] higher leukocytes 
MCP-1 [312] higher serum 
Heme oxygenase-1 [317] lower lymphocyte 
MCF2C [313] lower leukocytes 
INPP5D [314] higher leukocytes 
BIN1 [315] higher Whole blood 
ADNP [316] higher lymphocyte 
MGAT3 [318]  PBMC 
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miRNA can be attributed to specific organs and pathologies [330], making miRNA an ideal biomarker 
target [331]. 
 
Figure 7: Schematic showing the synthesis of miRNA 
A systematic review was conducted to extract all research articles looking at miRNA deregulation in 
the peripheral blood of AD patients (PubMed search terms “serum, plasma, blood, Alzheimer, 
biomarker and miRNA”). 19 articles were found in the literature; 18 articles were published between 
2012-2016 and one in 2007, summarised in Table 5. From the 19 articles [265, 332-347] 10 looked at 
serum blood samples [335-338, 341, 345, 347-350], 4 at plasma [339, 341, 342, 351], 3 at BMC [334, 
343, 352], 2 in exosomes [333, 340] and 1 in whole blood [332]. This corresponded to 56 miRNAs being 
found to be deregulated in serum, 10 in plasma, 11 in whole blood, 10 in BMC and 14 in exosomes as 
shown in Table 6. Sensitivity and specificity values were extracted from 6 articles, shown in Table 7. 
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Table 5: Summary of articles found after systematic review of miRNA deregulated in the peripheral blood in AD 
patients (PubMed Search terms “serum, plasma, blood, Alzheimer, biomarker and miRNA”) 
TOTAL NUMBER OF ARTICLES 19 
YEAR OF PUBLICATION 2012 to 2016 and 2007 
MOST FREQUENT TECHNIQUE USED TO DIAGNOSE AD  12 articles used MMSE 
MOST FREQUENT miRNA DETECTION TECHNIQUE USED 15 articles used PCR 
 
Table 6: Number of articles and miRNA found to be deregulated between AD patients and controls for different 
blood components. (PubMed Search terms “serum, plasma, blood, Alzheimer, biomarker and miRNA.”) BMC: 
Blood Mononuclear Cells 
 
  
BLOOD COMPONENT NUMBER OF ARTICLES NUMBER OF miRNA 
SERUM 10 56 
PLASMA 4 10 
WHOLE BLOOD 1 11 
BMC 3 10 
EXOSOMES 3 14 
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Table 7: Sensitivity and Specificity Values for the Diagnosis of AD using miRNA in Peripheral Blood. BMC: Blood 
Mononuclear Cells. WB: Whole Blood. 
AUTHOR REF NO. OF 
PATIENTS 
NO. OF 
CONTROLS 
BLOOD 
COMPONENT 
SENSITIVITY SPECIFICITY mIRNA 
PROFILE 
WANG (2015) [353] 97 81 Plasma 0.90 0.78 mir-107 
TAN (2014) [335] 105 150 Serum 0.87 0.53 mir-9 
0.81 0.68 mir-125b 
0.75 0.64 mir-181c 
TAN (2014) [338] 208 205 Serum 0.85 0.71 mir-342-3p 
0.81 0.68 mir-342-3p, -9
8-5p, 
885-5p, -191-5
p, 
483-3p, -7d-5
p. 
CHENG (2014) [333] 39 59 Serum 0.87 0.77 mir-30e-5p, -1
01-3p, -15a-5p
, -20a-5p, -93-
5p, -106b-5p, -
18b-5p, -106a-
5p, -1306-5p, - 
3065, -582-5p, 
-143-3p, -335-
5p, -424-5p, -3
42-3p, -15b-3p 
KUMAR 
(2013) 
[339] 31 37 Plasma 0.20 0.88 mir-545-3p 
0.95 0.53 let-7g-5p 
0.85 0.88 mir-15b-5p 
0.95 0.94 mir-545-3p, -7
g-5p, -15b-5p 
0.65 1 mir-142-3p 
0.95 0.76 mir-191-5p 
0.75 0.88 let-7d-5p 
LEIDINGER 
(2013) 
[332] 142 43 WB 0.92 0.95 miR-7f-5p, -12
85-5p, -107, -1
03a-3p, -26b-5
p, - 532-5p, -1
51a-3p, -161, -
7d-3p, -112, -5
010. 
BHATNAGGER 
(2014) 
[334] 110 123 BMC 0.92 0.96 mir-34a 
0.84 0.74 mir-34c 
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12 articles in the systematic review used the MMSE to diagnose AD; 10 gave an MMSE scores with the 
standard deviation. The numbers were extracted and compiled into the plot in Figure 8, which shows 
a decreasing progression of MMSE scores from MCI, with an MMSE score between 18-23, to severe 
cognitive impairment with an MMSE score of 10.  
Figure 8: Forest plot showing the distribution of MMSE scores from 10 articles. Study ID: 1. Kiko (2014) [342], 2. 
Cheng (2014) [333], 3. Leidinger (2013) [332], 4. Zhu (2014) [349], 5. Kumar (2013) [339], 6. Geekiyanage 
(2012) [346], 7. Wang (2015) [295], 8. Tan (2014) [338], 9. Dong (2015) [347] and 10. Tan (2014) [335] 
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2.3.7 Summary of miRNA as Alzheimer Disease Biomarkers 
The systematic review confirms the potential for miRNA diagnosis in AD [265, 332-347], however 
comparability between articles is difficult due to the differing patients’ MMSE scores as seen in figure 
8. There is also a lack of consistency in the published research as out of the 101 miRNAs found to be 
deregulated in AD, only 4 miRNAs were significantly deregulated in two different articles, 2 were 
consistently downregulated between articles (125b and 181c) and 2 were inconsistent, one was 
upregulated one downregulated (9 and 135a-5p) [335, 337, 345, 346, 350]. Both mir-9 and mir-181c 
have MMSE scores assigned to the two different articles, the first article has an average MMSE score 
of 10.5 and the second 15 [335, 346].  
The use of miRNA as biomarkers for AD shows sensitivities and specificities in line with the biomarker 
criteria as shown in Table 7 [191, 192], however the miRNA profiles with sensitivities and specificities 
above 85% have not yet been replicated in multiple peer reviewed journals, and  are not being used 
by clinicians or in clinical trials. If the methodology for miRNA detection could be standardised and 
participants miRNA levels in the peripheral blood compared to neuroimaging rather than MMSE 
scores, this could improve the consistency in the research.  
The systematic literature review showed that the MMSE scores of the participants used were 22 and 
above, therefore they fall into the MCI or AD category. If AD patients could be identified earlier when 
the pathology is less extensive this may improve the chances of finding a successful disease modifying 
treatment. Evidence shows that miRNA changes in the brain can be reflected in the blood. For example 
in a rat model for brain injury they found correlations between miRNA changes in the brain and blood 
[354, 355]. Along with Bekris et al. who conducted experiments in the post mortem brain, CSF and 
plasma of AD patients and found a correlation between the density of amyloid-β plaques and 5 miRNA 
levels, and one of the miRNA were also found to correlate with miRNA levels in plasma [265].Evidence 
such as the disruption to the BBB during AD and that 500 mL of CSF enters the blood daily means the 
miRNA could be transferred from the brain to the blood.  If it could be assumed that the miRNA 
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changes in the brain are reflected in the blood, then the AD post mortem brain samples collected in 
brain banks could be utilised to find miRNAs that correlate with the progression of the disease and 
find potential biomarkers to detect AD earlier in the progression of disease.   
2.5 Detection of miRNA 
There are three steps to RNA detection: sample collection, RNA isolation and RNA detection. Expected 
total RNA from serum or plasma can be up to 0.91 µg/mL, or 1 µg/1x106 in PBMC [356, 357] expected 
miRNA amounts can be up to 80 pg/µL in serum or plasma [357-360]. Figure 9 shows a typical process 
for RNA detection in blood samples. 
 
Figure 9: Process Diagram for the detection of RNA. 
2.4.1 Sample Collection 
The type of blood sample chosen can have a profound effect on the levels of RNA detected, for 
example, 427 circulating miRNA have been detected in either serum or plasma but not both, and 
different miRNA levels can be found in different sample types from the same individual [361-363]. The 
sample collection and pre-sample processing before isolation can affect the RNA detection levels. Such 
differences could be due to, whether a sample is processed fresh or from frozen, storage temperature, 
the amount of haemoglobin in the sample, the number of centrifugations to remove cell contaminants 
and the speed of centrifugation steps along with operator error [358, 360, 361, 364, 365]. The 
presence of blood cells can cause variation in the procedure due to the RNA in the cells contaminating 
the process, even though red blood cells do not contain a nucleus, measuring the haemoglobin in the 
sample can give an idea of the level of blood cell contamination [366]. The anti-coagulant chosen when 
collecting plasma can affect downstream processing. There are three main anticoagulants: citrate, 
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heparin and ethylenediaminetetraacetic acid (EDTA). Heparin has been found to inhibit PCR, whereas 
citrate and EDTA do not significantly alter RNA detection [367].  
2.4.2 RNA Isolation 
After sample collection and pre-processing RNA needs to be isolated. RNA can be isolated using a 
phenol/chloroform extraction (Trizol, Quizol, Trifast etc.) or by using commercially available kits 
containing spin columns and specific kits can be used for isolation of small RNA which includes miRNA. 
The resulting isolated RNA will vary in quality, size distribution, purity and yield depending on the 
isolation method used. For example, when isolating miRNA the miRNeasy serum and plasma kit gave 
an 8 fold higher yield when compared to the miVana PARIS kit [356, 365, 368, 369].  
Generally quality controls are conducted after isolation; this includes spectrophotometer analysis for 
RNA concentration and purity and gel electrophoresis to assess degradation. To evaluate the purity, 
absorbance is measured at 230 nm, 260 nm and 280 nm [370]. Absorbance at 230 nm corresponds to 
organic compounds for example Trizol or protein bonds, 260 nm corresponds to absorbance by nucleic 
acids and 280 nm proteins and phenolic compounds [370]. The ratio between 260/280 and 260/230 
is then determined, the 260/280 ratio should be ~2.0, a ratio lower than 2 represents contamination 
by proteins [370]. The 260/230 ratio should be between 1.8-2.2 for RNA samples, ratios lower than 
this can mean contamination by organic compounds for example Trizol and phenol [370].   
Gel electrophoresis determines the integrity of an isolated sample, this indicates how intact/degraded 
the RNA is. The technique separates the RNA sequences in the sample into size, which produces a 
specific band pattern, with the intensity of the band determining the amount of RNA. To calculate the 
integrity two bands are looked at, these correspond to the 28S and 18S ribosomal RNA, if the 28S:18S 
has a ratio of 2 or higher the RNA is considered good quality. Although these bands will not be present 
with small RNA which includes miRNA, only when total RNA is isolated. The integrity of RNA from 
samples can also be analysed using an Agilent bioanalyser, this is a microfluidic gel electrophoresis 
system that will generate a yield, size distribution and give an RNA integrity number (RIN) [371].  
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2.4.3 RNA Detection 
Once good quality RNA has been isolated, specific sequences can be quantified. From the systematic 
review, the predominant quantification technique was PCR [266, 332, 334, 335]. Other techniques 
included next generation sequencing (NGS) [337] and microarrays [336].  
2.4.3.1 Polymerase Chain Reaction (PCR) 
PCR is a two-step technique involving reverse transcription (RT) then the PCR step. The RT reaction 
converts RNA into DNA, called cDNA, then during PCR the cDNA is copied so there is an exponential 
increase in the number of copies and detected is generally based on fluorescence. RT works by 
attaching a small RNA sequence, called a primer, typically between 18-20 nucleotides to the RNA, then 
using a reverse transcriptase enzyme to expand the primer. miRNA RT is more complex, as miRNA 
sequences are generally between 20-22 nucleotides, and therefore primers are of similar length, There 
are two RT strategies for miRNA to overcome this: poly-A tails and stem loop primers as outlined in 
Figure 10 [372, 373].    
 
Figure 10: a) RT reaction from poly-A-tail primers, b) RT reaction using stem loop primers 
 
PCR involves heating the DNA to a high temperature to separate the double helix into single DNA 
strands, the DNA is then cooled to allow annealing of primers and then heated slightly for primer 
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extension. These 3 steps together are termed a cycle, which is repeated around 40 times, as shown in 
Figure 11. Quantification arises through binding of fluorescent tags to double stranded DNA. After 
each cycle the fluorescence is detected and plotted, theoretically amplification is expected to increase 
exponentially [374].  
Quantification arises by using appropriate controls (normalising genes) and simple calculations. These 
controls can lead to absolute or relative quantification of RNA. Absolute quantification is when sample 
PCR results are compared to a standard curve and relative quantification is when samples are 
compared to a reference. Each quantification strategy has its advantages and disadvantages. Absolute 
quantification is not dependant on the efficiency of the primers and the PCR optimisation needed is 
reduced, although it does require a standard curve so uses up wells in a PCR plate and expensive 
consumables. Relative quantification does not depend on a standard curve so is higher throughput 
when comparing to absolute quantification. However, relative quantification is dependent on the 
quality of the reference primers and that the efficiency of the reference and sample primers are similar 
[375].   
PCR is a widely used and well characterised technique with high specificity and a low detection limit, 
however, the technique is susceptible to contamination. To avoid PCR contamination the assay needs 
to be conducted in a dedicated workspace, and ideally each PCR step would be isolated in a different 
area, this would include separate workspaces for: sample preparation, PCR plate set-up and analysis 
of PCR products, with all surfaces and equipment being decontaminated before use [376]. Another 
way to prevent contamination includes aliquoting all reagents into DNAse and RNAse free 
consumables to prevent contamination in stock reagents and storing them separately. To identify 
contamination in a PCR procedure a negative control and no template control needs to be added into 
every PCR plate, a negative control only contains the PCR water used to set-up the assay, and a no 
template control contains the master mix and primers without the sample. Other disadvantages for 
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PCR include: its expense, time for detection, the need for specialised training and PCR cannot detect 
novel sequences due to the need for primers.  
 
2.4.3.2 Microarray  
Microarrays are used to determine the expression of thousands of miRNAs simultaneously. The 
technology is based on binding DNA sequences on a glass slide in specific locations in an array, so that 
the location of the different sequences are known, then a solution of fluorescently labelled sample 
miRNAs are added to the surface. From hybridisation of the sample to the bound DNA, miRNA can be 
quantified by reading the fluorescent intensity, which will correlates with the concentration of miRNA 
bound to the glass slide [377].  
Limitations of microarrays include the assumption that the intensity of the fluorescence is 
proportional to the concentration of miRNA sequences. In reality, there is only a small linear 
concentration range by which the assumption is valid. At high concentrations the surface can become 
saturated and at low concentration the equilibrium between binding and not binding to the surface 
favours no binding. Secondly, due to the similarities between miRNA sequences, the different 
Figure 11: Illustration of a 3 step PCR reaction: denaturing DNA, annealing primers and primer 
extension 
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sequences may bind to the same probe leading to inaccurate identity. Finally, microarrays will only 
detect miRNA if its complementary sequence is attached to the slide surface, therefore novel 
sequences cannot be detected [378]. Generally, microarrays are used to discover specific deregulated 
miRNAs as they are high throughput, then the deregulated miRNA are validated using PCR [336, 339].   
 
Figure 12: Schematic of a microarray, the fluorescent intensity correlates with the concentration of bound 
miRNA 
 
2.4.3.3 Next Generation Sequencing 
NGS is a high throughput sequencing technique. The advantage of NGS is it can detect unknown 
miRNA sequences, has a larger detectable concentration range and can quantify millions of miRNAs in 
parallel. NGS technology varies depending on the instrument, for example, detection can be either 
through fluorescence or a pH change [379, 380].  
For fluorescence-based detection, sequences are bound to a surface, then fluorescently-labelled 
terminated nucleotides are added individually (see Figure 13). After imaging, the fluorescence 
molecule is quenched, and terminating molecules are detached. The sequence is read one base at a 
time in subsequent cycles, the different bases are attached to a different coloured fluorescent signal 
so the identity of the base can be determined [381]. There are limitations in sequencing technology, 
as the technique has difficulty in sequencing homopolymer sections, low and high GC rich sections 
and long-read times lead to inaccuracies [382, 383]. Out of PCR, microarrays and NGS, the cost per 
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sample is high for microarrays, then NGS would be fractionally cheaper with PCR having the lowest 
cost [384]. 
 
Figure 13: Illustration of Next Generation Sequencing using Fluorescence as a Detection System 
 
2.4.3 Alternative techniques for miRNA detection 
The literature was searched for sensitive detection systems that have potential for miRNA detection. 
The systems identified: the quartz crystal microbalance (QCM) and other acoustic systems, 
electrochemistry, mass spectroscopy (MS) and surface plasmon resonance (SPR). These are explained 
in more detail in the following section. 
2.4.3.1 Quartz Crystal Microbalance and other acoustic techniques 
QCM is an acoustic piezoelectric detection technique that relies on the use of an AT cut quartz crystal 
sandwiched in a gold electrode for detection of a desired analyte. The AT cut of quartz is used as it has 
increased temperature stability between 10oC and 40oC when compared to alternatives [385]. Due to 
the piezoelectric and crystalline properties of the crystal, when a voltage is applied between the 
electrodes it induces a shear deformation in the crystal. When the frequency of an applied AC voltage 
matches the acoustic resonant frequency of the crystal the amplitude of the oscillation increases and 
the electric current into the electrodes increases. Therefore measuring the current in the electrodes 
can be used to find the resonant frequency [386, 387].  
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In 1959 Sauerbrey linked a change in resonance frequency to a mass loaded onto the electrode surface 
(Equation 1). Where △f is the experimentally measured decrease in resonance frequency (Hz), f is the 
intrinsic crystal frequency, △m is the elastic mass change (g), A is the electrode area (cm2), ρq is the 
density of quartz and µ is the shear modulus [388]. The Sauerbrey equation is only valid when a small 
pure elastic mass is added to the system, when the mass added is greater than 2% of the mass of the 
crystal the equation becomes invalid. This equation was also derived for measurements taken in 
vacuum, when one side of the crystal is immersed in liquid the system becomes more complex [388]. 
△ 𝑓 =
−2△𝑚𝑓2
𝐴(𝜇𝜌𝑞)0.5
= −𝐶𝑓 △ 𝑚         (Eq. 1) 
When operating in a liquid, the crystal is affected by both the viscosity and density of the solution, if 
the solution couples with the crystal, it will dampen the resonance and decrease the resonant 
frequency. The degree of damping can be calculated using the quality factor (Q). The quality factor is 
defined as the energy in the system over the amount of energy lost per oscillation, or the bandwidth 
of the oscillation relative to its central frequency. The higher the quality factor the lower the damping 
in each oscillation. The quality factor can be calculated using Equation 2, where f is the central 
frequency and B is the bandwidth [386]. 
𝑄 =
𝑓
2B
  (Eq. 2) 
The presence of the liquid in contact with the oscillating surface causes a wave to propagate into the 
bulk liquid, the penetration depth of this wave can be calculated using Equation 3 where: δ is 
penetration depth, η is the viscosity, f is the resonant frequency and ρ is the density [386]. However, 
it means energy is lost into the liquid from the crystal, which results in a slow damping of the 
oscillations. The point at which this energy loss is high enough to cause the crystal to stop oscillating 
can be calculated using the critical quality factor shown in Equation 4. Therefore, when the product 
of the viscosity and density moves above a threshold value, Q becomes lower than Q* causing the 
resonance frequency to cease [389].  
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𝛿 = (
2𝜂
(2𝜋𝑓𝜌)
)
0.5
 (Eq. 3) 
𝑄∗ = 2
𝐶𝑜
𝐶1
 (Eq. 4) 
In summary, resonant frequency can be affected by both mass and liquid, therefore a change in 
frequency can be attributed to either solution properties or mass loading. In 1991 Martin, Granstaff 
and Frye developed a model (Figure 14) that could differentiate change in frequency due to liquid and 
mass [387]. The model builds on the Butterworth-van Dyke model (BVD) for an unloaded unperturbed 
quartz crystal [386]. The unloaded crystal can be defined as a resister (R1), capacitor (C0, C1) and 
inductor (L1) [387, 390]. Capacitance is a systems ability to store electrical charge, inductance is the 
inertial component of the displaced mass and the resistance is the dissipation of energy due to internal 
friction [390, 391]. The diagram shows that when both liquid and mass is loaded into the system the 
capacitance does not change, with liquid loading the motional inductance and resistance increases 
and with mass loading only an increase in inductance. 
 
Figure 14: Diagram of an expanded Butterworth van Dyke model.  
 
Changes to the characteristics in Figure 14 will also affect the impedance. The impedance (Zm) 
represents the overall resistance of an alternating electric circuit and is a combination of the resistance 
(R1, R2) also referred to as the real resistance which is also seen when using direst current and 
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reactance or imaginary resistance arising from the alternating current and voltage. The 
reactance/imaginary resistance is the combined effect of the inductance (L1, L2 & L3) and capacitance 
(C1) [386].  
The literature explains that when QCM is operated in liquid it dampens the resonance and decreases 
the resonance frequency. The higher the product of the viscosity and density the more the frequency 
shifts and the motional resistance increases. A Newtonian fluid, a liquid where the viscosity is 
independent of the frequency, means the product of the viscosity and the density can be seen as a 
constant offset and is therefore the ideal scenario [392]. A viscoelastic liquid however exhibits both 
viscous and elastic properties so will resist shear flow. The general approach is to consider the acoustic 
impedance at the boundary between the electrode and the liquid. The imaginary impedance can give 
the frequency shift and the real impedance the damping. Examples and calculations can be seen in a 
paper written by Lucklum, Newton and Cowen. [393]    
The presence of the liquid means additional variables must be considered for example an increase in 
surface roughness will cause the resistance to increase and the resonant frequency to decrease. This 
is due to liquid becoming trapped in pits and crevasses on the surface causing mass loading, and 
contribute to the frequency shift [392, 394]. The wettability of the liquid will influence the effect of 
surface roughness. A more hydrophobic surface will mean the liquid will resist the shear movement 
more than a hydrophilic surface which will move with the oscillating surface. However it was 
experimentally determined that hydrophobic surfaces result in less energy dissipation and damping 
when compared to hydrophilic surfaces [389].  
QCM has been found to achieve detection limits for miRNA in the low fM and pM range when using 
nanoparticles to amplify the signal  [395, 396] and using direct label free detection sensitivities in the 
low µM range [397]. QCM can distinguish single base mismatches in miRNA sequences [397-399], 
detect selectively in mixed miRNA solutions [397] and miRNA can be detected in samples containing 
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75% serum, when comparing samples with 0% serum and 75% serum researchers achieved 67% 
recovery of miRNA [396, 400]. 
Other acoustic resonators include quartz crystal microbalance with dissipation monitoring (QCM-D) 
and surface acoustic wave (SAW) sensors. QCM-D is a QCM device that also measures the dissipation 
factor. Dissipation is the product of all energy lost in the system per oscillation and can be defined by 
Equation 5. Dissipation monitoring involves applying a frequency to the crystal then monitoring the 
decay in the resonance [386]. The dissipation of an oscillation provides information of how ridged or 
soft the attached surface layer is. If a layer is ridged it will follow the movement of the oscillation 
resulting in low dissipation, a soft surface will resist the oscillation causing high dissipation. When a 
molecule, for example a protein, is attached the surface it can change the viscoelastic properties of 
the surface layer and therefore change the dissipation [401].   
𝐷 =
1
𝑄
 (Eq. 5) 
SAW sensors, for example love wave sensors, are piezoelectric crystals with comb shaped interdigital 
electrodes. When an AC voltage is applied to one of the interdigital electrodes an acoustic wave 
propagates along the surface of the crystal to a second interdigital electrode which generates a 
measurable electrical signal [402]. If molecules are placed between the two interdigital electrodes it 
can alter the properties of the wave (properties include: wave propagation velocity, amplitude or 
resonant frequency), which can be measured using the electrical signal [403]. Love wave sensors have 
been found to have high sensitivities when used with a liquid interface [403]. These devices can also 
be designed for much higher frequencies, in the hundreds of MHz to the GHz range, when compared 
to QCM devices. The higher the resonant frequency the more sensitive the system as it reduces the 
penetration depth [402].  
2.4.3.2 Electrochemistry 
Electrochemical techniques are conducted in an electrochemical cell with a three-electrode system, 
consisting of a counter electrode, working electrode and reference electrode. All measurements 
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involve applying a potential to the working electrode using a potentiostat. If all electrodes are in an 
electroactive solution, the presence of the potential causes a current of ions to flow between the 
working and counter electrode. The current in the solution is then measured using the reference 
electrode. Many electrochemical techniques exist, including cyclic voltammetry and impedance 
spectroscopy [404].   
 
In cyclic voltammetry (Figure 16), the working electrode is set to a specific potential, V1, which is then 
increased linearly with time until a defined potential, V2, and then reduced back to V1. If the solution 
contains a redox species, then when the potential of the working electrode reaches the standard 
reduction potential of the redox species it will oxidise or reduce causing a peak in the current [405].  
Figure 15: Diagram of an electrochemical cell 
53 
 
 
Figure 16: Cyclic Voltamagram. Epc: Peak Cathodic Voltage. Epa: Peak Anodic Voltage. Ipa: Peak Anodic Current. 
Ipc: Peak Cathodic Current. 
 
Four values can be extracted from a cyclic voltammogram; (Figure 16) the peak anodic current (ipa), 
peak cathodic current (Ipc), peak anodic voltage (Epa) and peak cathodic voltage (Epc). The Ipc and Ipa can 
be used to determine whether the redox reaction Is reversible; this is when Ipc equals Ipa. When a 
reaction is reversible, the theoretical Ipc and Ipa can be calculated using Equation 6. Where n is the 
number of electrons in the half reaction, A is the area (cm2) of the electrode, c is the concentration 
(M), D is the diffusion coefficient (cm2 s-1) (for the electroactive species (using FeIII and FeII 
Do=0.718x10-6 cm2s-1 and Dr=0.667x10-6 cm2 s-1 [406]) and v is the sweep rate (V/s). For a reversible 
reaction, the theoretical peak separation (Epc-Epa) between the cathodic peak and anodic peak can be 
calculated using Equation 7, where R is the gas constant (J.mol.K), T is temperature (oC), n is the 
number of electrons and F is Faraday’s constant (C/mol) [407]. 
𝐼(𝑝𝑐 𝑜𝑟 𝑝𝑎) = (2.69 ∗ 10
8)𝑛3/2𝐴𝐶𝐷1/2𝑣1/2 (at 25oC)      (Eq. 6) 
𝐸𝑝𝑎 − 𝐸𝑝𝑐 =
2.22𝑅𝑇
𝑛𝐹
=
57.0
𝑛
(𝑚𝑉) (at 25oC)      (Eq. 7) 
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Cyclic voltammetry is commonly used to investigate the oxidation and reduction properties of 
molecular species [408]. However, there is evidence in literature showing that if molecules are 
attached to the surface of the working electrode it will reduce the peaks in the cyclic voltammogram, 
if the surface of the working electrode is completely blocked, then the peaks will not appear [409-
411]. From this information the technique may be used to determine the coverage of molecules on a 
functionalised surface.   
Electrochemical impedance spectroscopy measures impedance, which is a circuit’s ability to resist the 
flow of electrical current. During electrical impedance spectroscopy, a small sinusoidal potential is 
applied to the electrochemical cell and the responding alternating current can be used to calculate 
the impedance. The impedance can be split into both its real (x-axis) and imaginary parts (y-axis) and 
plotted into a Nyquist plot (Figure 17). This can then be fitted to the Randles circuit shown in Figure 
17. Rs is the solution resistance, Rct is the charge transfer resistance, Zw is the Warburg impedance and 
Cdl is the double layer capacitance, capacitance is a system’s ability to store electric charge [412]. 
 
Figure 17: Diagram of a) a Nyquist Plot and b) the Randles Cell.  
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The solution resistance is the resistance between the reference and working electrode. It is affected 
by electrolyte concentration, temperature, type of ions and geometry and area in which the current 
is carried. The highest point in the curve (wmax) is used to calculate both the double layer capacitance 
and charge transfer resistance. The double layer capacitance arises from the absorption of the charged 
ions in solution on to the charged metal surface of the working electrode. The ions and metal are 
separated by a small insulator space which acts as a capacitor. The resistance from the movement of 
charge between the metal working electrode surface and the ions in solution is the charge transfer 
resistance. The last characteristic, the Warburg impedance, which is at a 45o angle on a Nyquist plot 
(Figure 17) and is evident at low frequencies. The charge transfer resistance can be used to detect 
changes on the surface of the working electrode. 
Impedance spectroscopy has been used to detect miRNA [413-415]. However, to achieve biologically 
relevant levels, signal amplification strategies are used, this includes: using nanoparticles, redox 
chemistry and polymers [413-415]. Other electrochemical techniques have been used for miRNA 
detection including ampometry [416] and square wave voltammetry [417, 418]. Electrochemical 
techniques have reached sensitivities in the low fM level [415, 416] and have successfully detected 
miRNA sequences in physiological fluid [418]. 
2.4.3.3 Mass Spectroscopy 
MS is a technique that measures the mass of molecules. The technique involves ionising gaseous ions, 
accelerating the ions using an electric field and separating the ions according to size to measure the 
mass to charge ratio of molecules [407]. The ions can be separated using a magnetic field or in time 
of flight mass spectroscopy (TOF-MS) that uses a drift region where heavier ions will move faster [407]. 
Using amplification tags to increase the mass of miRNAs researchers have been able to selectively 
detect miRNA to the low fM level using TOF-MS. [419] and, using inductively coupled plasma-MS and 
an amplification strategy, were able to detect two miRNA simultaneously down to the low fM range 
in cell lysate [420]. MS measures the mass to charge ratio therefore it is difficult the differentiate 
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molecules that have the same mass and if the ions have more than a +1 charge it could make analysing 
spectra more problematic.   
2.4.3.4 Surface Plasmon Resonance 
Surface Plasmon Resonance (SPR) is an optical detection technique that measures the thickness of a 
layer. SPR relies on surface plasmons, these are electromagnetic waves that propagate along the 
boundary between a metal and a dielectric [407]. A dielectric is an electrical insulator, and when an 
electric field is applied it causes dielectric polarisation in the molecules. During SPR monochromatic 
light is directed into a prism and reflected by a layer of gold at the bottom of the prism into a detector. 
The bottom of the prism is coated with gold, then a surface layer for biosensing. When the angle of 
incidence of the monochromatic light reaches the angle of total internal reflection (where reflectivity 
would be 100%) and the surface plasmon is set up, it can reduce the reflectivity, this reduction is due 
to energy being absorbed into the gold layer [407, 421-423]. There are a few angles of incidence where 
the monochromatic light couples with the surface plasmon causing a dip in the reflectivity. If 
molecules are attached to the surface layer it can alter the angle at which the reflectivity dips [407, 
421-423]. 
SPR has been used to detect miRNA at the low fM level within 30 mins [424, 425]. However many of 
the researchers used signal amplification strategies by labelling with streptavidin or nanoparticles 
[425-427]. SPR detection has recently been able to detect 2 miRNAs simultaneously [426], 
differentiate sequences with a single mismatched base [425, 427] and detect miRNA spiked in human 
serum [425].  
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2.6 Conclusions  
Early detection of AD has many benefits, for example diagnosis would be while neuropathology is in 
its infancy so could increase the significance of a disease modifying therapy which delays the 
progression of AD or increase the recruitment of patients into clinical trials. More advantages of early 
detection and the ethical implications are outlined in section 1.1.  
Currently the earliest point an AD patient can be diagnosed is when they visit their GP after onset of 
symptoms. At this point symptoms could be because of several causes, and patients normally undergo 
medical tests in order to rule out other causes of memory impairment. At this point AD pathology in 
the brain is extensive. If a biomarker could be developed that correlated with the amyloid-β deposition 
or Braak stage of the patient, then the marker could identify individuals before onset of symptoms to 
determine individuals at risk of developing AD. These individuals can then be referred for more 
medical testing.  
From the literature gathered, miRNAs show promise as an early biomarker for AD. This is because 
miRNAs have been found to be deregulated in patients with MMSE scores as low as 22, when a patient 
is borderline cognitively normal [333, 342]. Along with the evidence from Bekris et al who found that 
mir-15a shows a positive correlation with amyloid-β and increases in the plasma of AD patients [265]. 
The ability to predict the extent of the amyloid-β deposition or Braak score from the peripheral blood 
is beneficial for a screening test therefore detection techniques need to be cheap and reliable. Current 
techniques have been able to accurately quantify miRNAs in serum without pre-sample processing, 
techniques including QCM  [400] and SPR [425]. 
The development of a miRNA AD biomarker for early screening is logistically difficult as samples would 
need to be obtained from a large group of individuals over time. Therefore, initially it would be 
beneficial to test the hypothesis that miRNA sequences could correlate with Braak score in the brain 
of AD patients. Then more logistically challenging investigations can be conducted.    
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Chapter 3: Deregulation of 
miRNA in the Temporal Cortex 
through the Progression of 
Alzheimer’s 
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3.1 Introduction 
3.1.1 Aim of the chapter 
There are several studies which have looked at the deregulation of miRNA in the brain of patients with 
AD  [258, 428-432]. However, many of the journals use Braak stage I-II as a control to compare to 
Braak stages III-VI. This chapter aims to determine the levels of specific miRNA through the 
progression of AD by using Braak stage 0 as control samples and comparing to Braak stage I-VI. As it 
was hypothesised that the pathological miRNA changes seen in the brain could be reflected in the 
peripheral blood and therefore the strategy could be used to identify early deregulated miRNA 
suitable for biomarker diagnosis. 
3.1.2 Introduction 
A systematic review was conducted to look at the deregulation of miRNA in the brain of AD patients. 
This was done to establish the miRNA sequence found to be deregulated in the brain and determine 
which miRNA sequences may be a good target for analysis. 27 articles were found looking at 
deregulated miRNA in the brain, corresponding to 250 miRNAs. The search included 13 articles from 
the temporal cortex [430, 433-444], 6 from the hippocampus [258, 428-432], 8 from the frontal cortex 
[258, 428, 445-450], 1 from the entorhinal region [432] and 1 the parietal lobe [451]. The articles that 
defined the Braak stage were extracted and split into three groups: Braak stage I-II, Braak stage III-IV 
and Braak stage V-VI. Braak stage I and II were used as control cases, therefore no miRNAs was found 
to be deregulated. 27 miRNAs were deregulated at Braak III-IV and 99 at Braak V-VI, shown in Figure 
18. The changes in miRNA levels as a patient progresses through the Braak stages could be due to 
various reasons. For example, the loss of neurones means there is a higher proportion of other cell 
types, including microglia and astrocytes, so may result in reduced levels of neuron enriched miRNA. 
A second reason could be the increase in neuroinflammatory factors due to activated astrocytes and 
microglia.  
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From the literature 19 miRNAs were found to be deregulated in the AD brain at Braak stage III-IV. Due 
to time restrictions and cost it was decided to only test 5 miRNA sequences. From the 19 miRNAs 
deregulated in the brain 4 were chosen: mir-30c, mir-27b, mir-425 and mir-210. mir-30c 
downregulates in response to amyloid-β 42 [452] and has been found to have high expression in 
astrocytes [453]. mir-27b has been found to be highly expressed in the brain [454] and enriched in 
astrocytes, however this was found in a mouse model [455], also in a mouse model mir-27b has been 
found to regulate more than 100 mRNAs involved in presynaptic neurons [454]. mir-425 is expressed 
in mouse astrocytes [455]. mir-210 increases the expression of vascular endothelial growth factor 
(VEGF) [456]. VEGF regulates angiogenesis and inflammatory responses. Increased VEGF levels can be 
found in the temporal cortex of AD patients [457].  Table 8 shows the areas of the brain and at what 
Braak stage each miRNA is deregulated. A further miRNA, mir-223, was also chosen. mir-223 regulates 
glutamate receptors GluR2 and NR2B [458]. Glutamate regulation is altered in AD (outlined in Chapter 
2). The evidence shows that three of the chosen miRNAs are also deregulated in the peripheral blood 
of AD patients, these are: mir-30c [337], mir-210 [349] and mir-223 [350].   
  
Figure 18: Illustration showing the deregulation of miRNA during the progression of Alzheimer’s. 
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Table 8: Deregulation of mir-30c, mir-27b, mir-210 and mir-425 in the brain of AD patients. 
mIRNA DEREGULATION BRAIN AREA BRAAK STAGE Ref 
mir-30c Down Hippo III-IV [258] 
Up Frontal III-IV [258] 
mir-27b Up Hippo III-VI [258] 
Up Frontal V-IV [258] 
mir-210 Down Hippo III-VI [258] 
Down Frontal V-IV [258] 
Down Temp - [435] 
mir-425 Down Hippo III-VI [258, 428] 
Down Frontal III-IV [258] 
mir-223 Up Temp V-VI [433] 
 
3.2 Materials and Methods 
Brain samples were obtained from Manchester Brain Bank. The miVana isolation kit and Trizol reagent 
was purchased from Thermo Fisher Scientific and the Direct-zol isolation kit from Cambridge 
Biosciences. Absolute ethanol, isopropanol and chloroform were all molecular biology grade from 
Thermo Fisher Scientific. An RNA Nano 600 kit was obtained from Agilent Technologies. All PCR 
reagents were purchased as part of the Qiagen miScript kit, specifically the miScript II RT kit, miScript 
SYBR green PCR kit and miScript primer assays. RT used an oligo(dT) primer supplied as part of the kit 
and PCR primers were Hs_miR-27b_2, Hs_miR-223_1, Hs_miR-30c_2, Hs_miR-425-3p_1, 
Hs_miR-210_1 and Ce_miR-39-5p_1. Synthetic RNA cel-mir-39 (AGCUGAUUUCGUCUUGGUAAUA) was 
bought from Integrated DNA Technologies (IDT).  
3.2.1 Brain Samples 
Frozen medial temporal cortex samples were obtained from Manchester Brain Bank, under their 
ethical approval, in accordance with HTA guidelines. The bank supplied anonymous samples along 
with the diagnostic pathology, gender, age, Braak stage, post-mortem interval (PMI) and pH. The 
medial temporal cortex was chosen as this contains the hippocampal and entorhinal region [459] 
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where tau pathology develops early in AD progression [27]. It was chosen to use brain tissue rather 
than blood as the aim of the chapter was to determine if deregulated miRNA in the brain correlate 
with Braak stage. Only Braak stage was used to compare with miRNA, as tau pathology has been 
correlated with cognitive decline [460, 461], evidence suggests that between 8% to 12% of cognitively 
normal individuals can contain extensive tau pathology however, all samples obtained above Braak 
stage V had been clinically diagnosed with AD. In total 28 anonymous brain samples were acquired. 
All sample information is shown in Appendix I. Initially 8 samples were received as shown in Table 9. 
The samples were split into 4 groups depending on their pH and PMI.  
Table 9: Brain Sample Information 
SAMPLE GENDER  AGE BRAAK STAGE PMI (h) pH 
16/18 F 94 I 58.5 5.88 
15/29 M 81 V-VI 68 6.03 
16/31 M 90 I-II 155 5.64 
16/14 F 92 V-VI 118 5.94 
14/11 M 91 I-II 43.5 6.32 
13/16 F 89 IV-V 56 6.36 
13/11 F 96 IV-V 154 6.35 
13/12 F 89 II-III 134 6.35 
 
A second batch of 20 samples was then received as indicated in Table 10. The samples were grouped 
according to Braak stage, the total RNA was isolated using Trizol reagent and miRNA levels determined 
using PCR. This included 4 samples at Braak stage 0, 4 samples at Braak stage I-II, 5 samples at Braak 
stage III-IV and 6 samples at Braak stage V-VI.      
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Table 10: Brain Sample Information 
SAMPLE GENDER  AGE BRAAK STAGE PMI (h) pH 
09/15 F 89 V-VI 72 - 
09/17 M 76 V-VI unknown  - 
09/24 M 78 0 144 - 
10/01 F 78 III-IV 81 - 
10/08 F 87 V-VI 60 - 
11/16 M 64 V-VI 75 - 
12/01 M 67 V-VI 84 - 
12/09 F 87 I-II 87 - 
12/11 M 54 0 37 - 
12/16 F 53 0 92.5 - 
12/23 M 95 I-II 12 - 
12/32 M 73 V-VI 36 6.63 
14/01 F 93 II-IV 70.5 - 
14/18 M 77 III-IV 162 6.04 
14/27 F 90 I-II 121 5.81 
16/01 M 90 III-IV 26 - 
16/06 F 45 0 71 5.95 
16/08 M 88 III-IV 114 5.54 
16/38 F 76 I-II 113.5 - 
16/43 M 87 III-IV 92.5 - 
 
 
Figure 19: Age and PMI for brain samples in Table 9. Statistical significance between groups measured using ANOVA. 
Significance found between age of patients at Braak 0 and age of patients in all other groups. 
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3.2.2 RNA Isolation 
Total RNA was isolated for the first 8 samples using 3 different isolation protocols: the Ambicon 
miVana kit, the Zymo research Direct-zol kit and the trizol/chloroform extraction. Before extraction 
tissue samples were aliquoted by cutting on dry ice. The manufactures protocol was followed for all 
isolation protocols. In brief, the miVana kit involved lysing the samples using the lysis buffer provided, 
incubating in homogenate additive then centrifuging after addition of acid-phenol:chloroform. After 
centrifugation the upper aqueous layer was removed, the solution was washed in ethanol using spin 
columns, then eluted with heated RNAse-free water.  
For the Direct-zol kit, the tissue was lysed by pipetting up and down with a 1 mL pipette in Trizol 
reagent until the sample was homogenised, then an equal volume of ethanol was added, and the 
mixture passed through a spin column. The RNA was DNAse digested on the spin column then washed 
with the RNA prewash and RNA wash buffers provided. The RNA was then eluted using RNAse-free 
water. 
Trizol reagent was added to the samples and left overnight at 4oC to soften the tissue, the tissue was 
then disrupted by pipetting up and down using a 1 mL pipette until the sample was lysed. Chloroform 
was added according to the manufactures protocol and the phases separated. The RNA was 
precipitated with 100% isopropanol overnight at -20oC then washed in 75% ethanol and resuspended 
in RNAse-free water.   
3.2.3 RNA Quality 
All isolated samples were analysed on a nanodrop 2000 at 230 nm, 260 nm and 280 nm, then the 
260/280 and 260/230 ratios determined. The RNA degradation was determined using an Agilent 
bioanalyzer with the RNA 6000 Nano kit, following the manufacturers protocol.  
3.2.4 PCR 
RNA samples were DNAse digested using the DNAse I, RNAse free set from Life Technologies. 1.5 µg 
of RNA was diluted into 11 µL of RNAse free water and then 1 µL of DNAse I and 1 µL of 10x reaction 
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buffer (with MgCl2) was added, the samples were heated at 37oC for 30 min. 1 µL of 50 mM EDTA was 
added then heated at 65oC for 10 min.  
After DNAse treatment, the Qiagen miScript II RT kit was used for RT. 4 µL of 5x HISPEC buffer, 2 µL of 
10x nucleics mix, 2 µL of RT mix, 1 µL of synthetic cel-mir-39 (0.69 µg) was added to the samples after 
DNAse digestion (as a spike-in control). The samples were heated at 37oC for 60 min, 95oC for 5 min 
then cooled on ice. Then samples were made up to 200 µL with RNAse free water and the amount of 
nucleic acid in the sample measured using a Nanodrop. 
PCR experiments were conducted on a Step One Plus PCR machine using the miScript SYBR green kit. 
All samples were run in triplicate with negative controls. Reaction mixes contained 12.5 µL of SYBR 
green mix, 2.5 µL of universal primer, 2.5 µL of primer assay, 2.5 µL of sample and 5 µL of water. The 
PCR cycle consisted of heating to 95oC for 15 min, then 40 cycles of 15 s at 94oC, 30s at 55oC and 30 s 
at 70oC, all cycles ended with melt curve analysis using the Step One PCR machine protocol.   
The PCR results were normalised using the spike in control, this was the synthetic RNA cel-mir-39 
which was spiked into the sample before RT. The ΔΔct method was used for analysis, this involved 
normalising the miRNA ct value to the spike in ct value and then normalising to Braak stage 0 samples 
[462]. Statistical significance was tested using ANOVA in GraphPad.  
3.3 Results 
3.3.1 Sample Isolation 
Initially 8 samples were received with varying pH and PMI (Table 9), the total RNA was isolated, and 
the RNA quality tested. This was to determine if the PMI and pH of the tissue can be used as an 
indicator of RNA quality. RNA was isolated from all 8 samples using the miVana isolation kit, the 
direct-zol isolation kit and the trizol/chloroform extraction protocol. Samples were then analysed for 
purity and integrity. After nanodrop analysis the average 260/280 values and 260/230 values were 
2.05 and 2.11 respectively, indicating all protocols resulted in samples free from contaminates. The 
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direct-zol kit resulted in lower yield of isolated RNA (Figure 20) and more variable absorbance ratios 
between samples, indicating the presence of contaminants, so the direct-zol kit samples were not 
processed any further. 
 
Figure 20: RNA yield and Nanodrop 260/280, 260/230 ratios from brain sample isolation using miVana kit, 
Direct-zol kit and the Trizol protocol. Bars show the mean value with error bars depicting SD (n=8).   
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Figure 21: Effect of pH and PMI on RIN values of isolated RNA a) effect of pH, b) effect of PMI. PMI: Post 
Mortem Interval.  n=8).   
The miVana and Trizol samples were assessed for integrity using the Agilent bioanalyzer, the average 
RIN number was 2.85, suggesting the isolated RNA was degraded. All bioanalyzer data is in appendix 
II. The RIN was higher in samples with a lower PMI (below 70 hours) and when the pH was above 6, 
significance was tested using Pearson’s correlation coefficient, only pH vs. the Trizol method was 
found to be significant (p=0.048) (Figure 21).  
After the initial 8 samples were isolated it was decided to use the trizol protocol due to the higher 
average yield. Additionally, when using trizol, homogenisation was easier as the tissue was softened 
when incubated in the trizol, so hominization was easier. A further 20 samples were obtained from 
the Manchester brain bank and isolated in one batch (Figure 22), resulting in an average 260/280 ratio 
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of 1.95, 260/230 ratio of 1.68 and an RIN of 2.4 (all bioanalyzer data available in appendix III). This 
was comparable to results seen in Figure 20.  
 
 
Figure 22: Nanodrop 260/280 and 260/230 and Agilent bioanlayser RIN number for samples isolated from 
Table 3.2.1b. Bars show the mean value with error bars depicting standard deviation (n=20). 
 
Figure 23: Agilent bioanlayser RIN number for samples isolated from Table 10. Bars show the mean value with 
error bars depicting standard deviation (n=20).   
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3.3.2 PCR Efficiency 
Before analysing miRNA in brain samples, the PCR stem-loop primers (purchased from Qiagen) were 
tested to ensure efficient PCR. This was conducted because relative quantification of PCR assumes 
exponential amplification, this means after every PCR cycle the cDNA is doubled. Therefore, the 
primers were tested to determine if the assumption is true.  The efficiency was tested for the 6 miRNA 
primers: cel-mir-39, mir-210-3p, mir-30c-5p, mir-27b-3p, mir-425-3p and mir-223-3p. The PCR 
efficiency was tested by generating a standard curve using the cDNA product, and a dilution factor of 
2, this was so that 4 points could be tested within the detection limits of the miScript PCR kit, all points 
on the curve were tested in triplicate (method taken from [463]). The literature suggests that the 
efficiency of primers should be from 90% to 110% and have an R2 value above 0.9 [375, 464, 465].  
Melt curves in Figure 24 show one distinct peak and therefore one product for all miRNA except 
mir-425. For mir-425 the PCR annealing temperature was altered to between 54oC to 57oC, however 
this still resulted in more than 1 product, so no further work was conducted with this primer. The 
graphs in Figure 25 show a clear linear trend with all R2 values above 0.9 and efficiency values above 
84%. All primers except for mir-30c had both an efficiency between 90% to 110% and R2 above 0.9. 
Attempts were made to improve the efficiency of mir-30c, although these were unsuccessful.  
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Figure 24: Melt curves generated using Step One Plus PCR machine. Using primers: a) 
Ce_miR-39-5p_1, b) Hs_miR-223_1, c)  Hs_miR-27b_2,d)  Hs_miR-210_1, e) Hs_miR-30c_2  and 
f) Hs_miR-425-3p_1 (Qiagen) (n=3) 
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Figure 25: Graphs showing the Ct values (extracted from PCR software) vs log concentration for the 5 primers: 
a) Ce_miR-39-5p_1, b) Hs_miR-223_1, c) Hs_miR-210_1, d) Hs_miR-30c_2 and e) Hs_miR-27b_2. Graphs show 
the mean values with error bars depicting standard deviation (n=3).   
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Table 11: Efficiency of PCR with 5 different primers: Hs_miR-27b_2, Hs_miR-223_1, Hs_miR-30c_2, 
Hs_miR-425-3p_1, Hs_miR-210_1 and Ce_miR-39-5p_1. Analysis from graphs shown in Figure 25. 
miRNA EQUATION OF THE LINE EFFICIENCY R2 
SPIKE Y = -3.559*X + 20.65 90.98% 0.99 
223 Y = -3.365*X + 42.37 98.23% 0.94 
27b Y = -3.365*X + 42.37 98.23% 0.94 
210 Y = -3.365*X + 42.37 98.23% 0.94 
30c Y = -3.776*X + 41.89 84.01% 0.97 
 
3.3.3 miRNA PCR 
5 miRNAs (cel-mir-39, mir-210, mir-27b, mir-30c and mir-223) were analysed by PCR using all samples 
in Table 10. Figure 26 contains results using the ΔΔct method. No significant differences were found 
for any of the miRNA with respect to the Braak stage.  
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Figure 26: PCR data from samples in Table 10. Braak 0 n=4, Braak I-II n=4, Braak III-IV n=6 and Braak V-IV n=6. 
Statistical significance tested using ANOVA. Graphs show the mean values with error bars depicting standard 
deviation. 
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3.4 Discussion  
3.4.1 Quality analysis of brain samples 
Research into the deregulation of miRNA in AD is dependent on access to good quality brain tissue 
containing RNA with high integrity. The use of tissue samples stored in brain banks would be ideal. 
However, there are various factors that could contribute to degradation of RNA in tissue, including: 
sample processing before storage [466-468], PMI [469-473], average brain pH [470, 471, 474] and 
agonal events preceding death (coma or hypoxia) [475].  
The experiment in Figure 21 determined that pH and PMI had no significant effect on the integrity of 
the RNA (RIN value). The literature shows no correlation between PMI and mRNA degradation for 
PMI’s up to 40 hours [469-472], and no effect on PCR ct values up to 118 hours [476]. The highest PMI 
used in experiments was 155 hours, only one study could be found using PMI’s above 155 hours, they 
concluded that only PMI’s up to 72 hours should be analysed by PCR [477]. Positive correlations have 
been found between the pH of brain tissue and RIN of mRNA, especially when the RIN is below 7 [470, 
471, 474].  
Agonal events, for example respiratory illness, artificial ventilation and coma duration can induce 
acidosis in the brain, therefore the pH of the brain is an indicator of these events [478, 479]. Studies 
show that agonal events will decrease the mRNA quality according to the RIN [480] and positive 
correlations have been found between the pH of brain tissue and RIN of mRNA, up to a pH of 7 [470, 
471, 474]. Evidence also shows that the sex of the participant, age of the participant at death and the 
diagnosis of any neurodegenerative disorders also have a significant effect on mRNA integrity. 
However, 83% of the samples had a PMI under 24 hours [480].  
It could be hypothesised that the agonal state and in combination the pH has a more significant effect 
on the mRNA RIN value when compared to PMI, as studies have found a correlation between pH and 
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RIN values and no correlation between PMI and RIN [481] also when participants that had experienced 
hypoxia before death are excluded there is no correlation between RIN and pH [473].   
3.4.2 miRNA analysis according to Braak stages 
Results in Figure 22 clearly show the isolated total RNA had an average RIN of 2.4. For mRNA analysis 
the degradation could lead to inaccurate quantification using PCR [482]. However, evidence suggests 
that the RIN value has a negligible effect on miRNA PCR [356, 482, 483]. This may be because miRNA 
have increased stability when subjected to ribonucleases [484], are stable when incubated at room 
temperature (below 4 hours) and through several freeze thaw cycles [485]. miRNA have been found 
to decay in brain tissue [440] , although PCR was not used to analyse the degradation. Agonal state 
has been found to decrease the gene expression profile in microarray’s, and post-mortem factors like 
PMI showed no correlation to the profile [475]. 
Analysing miRNA levels in the AD brain could identify miRNAs that correlate with Braak stage, and this 
information could be useful as analysis of miRNA could lead to therapeutic targets or potential 
biomarkers for diagnosis. To my knowledge there are no articles analysing miRNA through all Braak 
stages in the temporal cortex, the closest is Cogswell et al, who analyses miRNA levels from Braak 
stage III-IV in the hippocampus and frontal cortex [258] and this study was conducted using temporal 
cortex samples.  
From the 4 miRNAs analysed, no miRNA showed significant deregulation when correlated against 
Braak stage (Figure 26).  The literature shows that mir-30c is downregulated in the white matter of 
the temporal cortex in AD brain tissue [433]. mir-27b is upregulated in both the hippocampus [258] 
and frontal cortex [258] of AD patients. Increased levels of mir-223 can be seen in the hippocampus 
[428] and down-regulation of mir-210  in the temporal cortex, the Braak stage could not be identified 
[435]. Therefore, significant differences were expected for all miRNA’s analysed. There could be 
several reasons for the contradictory results, including: the degradation of the RNA samples, the 
variation between the samples or the differences in the PCR primer efficiencies.   
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The effect of miRNA degradation is still largely unknown as the RIN is more indicative of longer mRNA 
sequences, therefore the level of miRNAs in the test samples could have been significantly lower than 
at 24 hours, which was a common PMI of samples used in the literature. The pH of the sample, which 
is indicative of agonal events, could have impacted the results, the pH was unknown for many of the 
samples so this could not be determined.  The second reason for the inconsistency between the 
experimental results and the literature is the sample variation, there are three ways in which the 
variation could be improved. The first would be to look for a biological miRNA reference gene, so that 
biological variation could be accounted for in the analysis. The second amendment would be to have 
an additional spike in control, added after homogenising the tissue, this would account for the 
variability in the RNA extraction procedure. Finally, the amount of RNA used in the PCR experiment 
could have been calculated from the amount of small RNA rather than total RNA, to reduce the 
variation in the amount of RNA used from each sample in the PCR experiment. Another reason for the 
contradictory results could be due to PCR efficiency, a small change in the efficiency between primers 
could lead to a large change in results. Although the literature suggests an efficiency range of 90% to 
110%, which is a 20% range, and the efficiency range in experiments was 14%.   
Some of the limitations in the experiment include: the small sample sizes, highly degraded samples 
and long PMI’s. Before increasing the number of samples, the variation from the experimental design 
would need to be accounted for. The effect of long PMI’s on miRNA quantification is still relatively 
unknown [469-472, 476, 477]. If access to samples with lower PMI’s could be obtained a comparison 
could be made between PMI’s and miRNA quantification using PCR. Other improvements to the 
chapter could be to sequence the PCR product to confirm the amplified product matches the sequence 
the experiment aimed to quantify.  
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3.5 Conclusions  
The aim of the chapter was to identify if deregulation of miRNA in the AD brain correlates with Braak 
stage. As it was hypothesised that if the changes in the brain are reflected in the peripheral blood, this 
could identify potential early biomarker targets. However, no significant differences could be found 
with the 4 miRNA sequences tested, so if the hypothesis is true these miRNAs would not be an ideal 
biomarker target.  
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Chapter 4: Effect of 
Transfected miRNA on 
Astrocytes in vitro 
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4.1 Introduction 
4.1.1 Aims  
The literature shows there are 250 deregulated miRNAs in the brain of AD patients, this chapter looks 
to determine the effect 5 of these miRNAs have on activated astrocytes. Activation of astrocytes are 
one of the earliest pathological features of AD [105-107] and some of the earliest miRNAs found to be 
deregulated in the brain of AD patients are: mir-27b, mir-30c, mir-210, mir-223 and mir-425 [258, 428, 
433, 435, 436]. This chapter tests the hypothesis that some of the earliest miRNA found to be 
deregulated in the brain could affect the activated astrocytes and contribute towards some of their 
altered roles in the AD brain. Some of these altered roles include the dysfunction in the 
glutamate/glutamine cycle [146] and increased levels in secreted factors.  This could give an insight 
into the role of miRNA in AD and if they could be used as a therapeutic target.    
Therefore, there were two clear aims. The first to activate astrocytes and determine activation using 
inflammatory cytokines and GFAP expression. The second was to transfect the activated astrocytes 
with mir-27b, mir-30c, mir-210, mir-223 and mir-425 and measure changes in metabolism, secreted 
growth factors and cytokines.  
4.1.2 Introduction 
The literature shows deregulation of mir-27b, mir-30c, mir-210, mir-223 and mir-425 in the brain of 
AD patients. mir-30c, mir-210 and mir-425 are downregulated and mir-27b and mir-223 was 
upregulated [258, 428, 433, 435, 436]. miRNA can be deregulated in AD because of neuronal cell death 
as the loss of neurons can lead to downregulation of neuron enriched miRNA. Another reason can be 
through alterations in the enzymes that control miRNA production for example Dicer or Drosha [486]. 
Finally deregulation of miRNA can also arise through increased inflammatory cytokines, increased 
expression of amyloid-β or tau in neurones [452]. 
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The activation of astrocytes is an early event in AD [105-107] and is characterised by an upregulation 
in GFAP [110], a ramified phenotype, neurotoxic glutamate build-up [487], and increased 
inflammatory cytokine production [216, 488]. Astrocytes can be activated in vitro using LPS [489, 490] 
and TNF- α [491]. LPS and TNF-α were chosen as the literature shows they can activate the 
astrocytoma cell line (U373) used in the study [489-491]. High TNF-α levels in the central nervous 
system has been linked to AD and in mice TNF- α has been correlated with cognitive decline, along 
with abnormal APP processing, amyloid deposition, tau pathology and cell death [492, 493]. LPS is 
more indicative of a bacterial infection, however LPS has been found to accumulate in the neurones 
of the AD brain and in rat experiments LPS has been found to induce cognitive dysfunction and 
accumulation of amyloid [494, 495].  Activation in this project was tested by measuring the expression 
of GFAP [496], secretion of NO [497, 498] and IL-6 (interleukin 6) [499-501].  
To test the hypothesis that mir-27b, mir-30c, mir-210, mir-223 and mir-425 can affect astrocytes after 
activation, the cells were activated first then transfected with the miRNA sequences, so the miRNA 
were overexpressed. To describe the status of the astrocytes after the transfection the following 
factors were measured: NO, IL-1β (Interleukin 1β), IL-10 (Interleukin 10), BDNF (brain-derived 
neurotrophic factor), MMP-9, GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) and 
G-CSF (Granulocyte Colony Stimulating Factor), along with the production or consumption of glucose, 
lactate, glutamate, glutamine and ammonia. Three of the factors: pro-inflammatory IL-1β [502, 503], 
anti-inflammatory IL-10 [504] and BDNF have altered levels in post-mortem AD brains and aid in the 
progression of the disease. IL-1β [505] and IL-10 are higher [504] and BDNF is lower [506-508]. IL-1β 
aids in the progression of AD by maintenance of chronic inflammation [509]. However, attempts to 
reduce the inflammation by administering IL-10 to an AD mouse model resulted in amyloid-β 
accumulation from reduced phagocytosis by microglia [510]. Reduced BDNF signalling impairs spatial 
memory [506], and BDNF therapy in an AD mouse model improved symptomatic learning and memory 
deficits [511].  
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MMP-9 shows no significant difference in the frontal cortex of post-mortem AD brains [512], and the 
levels of GM-CSF and G-CSF are unknown. However, overexpression of these factors has been found 
to improve cognitive impairment in AD mouse models [513-515] and G-CSF has also been found to 
improve hippocampal dependant cognitive performance in human patients [516]. All of these factors 
have been found to be secreted by activated astrocytes [294, 513, 514]. MMP-9 aids in the clearance 
of amyloid-β [515], both GM-CSF and G-CSF reduce amyloidosis [517-519] and GM-CSF has 
antiapoptotic properties [520].   
The consumption or production of glucose, lactate, glutamate, glutamine and ammonia was also 
determined after miRNA overexpression. Deregulation of these metabolites can lead to reduced 
neural support. in AD there is reduced glucose metabolism [201, 521] and reduced uptake of 
glutamate [487] by astrocytes. Leading to lower lactate production for energy and hippocampal 
memory formation [522] and glutamine supply for synaptic transfer.    
4.2 Materials and Methods 
U373 astrocytoma cells were purchased from ECACC (European Collection of Authenticated Cell 
Cultures). EMEM (Eagle’s Minimum Essentials Media), L-glutamine, 1% non-essential amino acids, 
sodium pyruvate, LPS, IL-1β, napthylethylenediamine dihydrochloride, sulphanilamide, phosphoric 
acid, bovine serum albumin and methanol were from Sigma Aldrich. Anti-mouse GFAP monoclonal 
antibody (conjugated to alexa fluro 488) (53-9892-82), lipofectamine RNAiMAX, IL-6 human uncoated 
ELISA kit (88-7066-22), molecular biology grade absolute ethanol, concentrated 37% hydrochloric acid 
(HCL), TrypLE express, 4% paraformaldehyde (PFA), foetal bovine serum, 0.25% tripsin/EDTA, 1x 
Phosphate Buffer Saline (PBS) (no Mg or Ca), Bovine Serum Albumin, 10 M borate buffer and 
methylene blue were from Thermo Fisher Scientific. A custom human pre-mixed Luminex kit was 
purchased from R & D systems. Glucose, lactate, glutamate, glutamine and ammonia cassettes for the 
CEDEX were obtained from Roche.  
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4.2.1 Cell Culture 
U373 astrocytoma cells were cultured in EMEM supplemented with 2 mM L-glutamine, 1% 
non-essential amino acids, 1 mM sodium pyruvate and 10% foetal bovine serum. Cells were seeded at 
20,000 cells/cm2 changing the media every 2-3 days and passaging with 0.25% trypsin/EDTA or TrpleE 
at 80% confluency. Cells were grown at 37oC with 5% CO2.  
4.2.2 Astrocyte Activation 
U373 cells were seeded at 20,000 cells/cm2 into either well platers or flasks and left overnight to 
attach. Then one or both of 50 ng/mL TNF-α and 1 ug/mL LPS was supplemented into the media and 
incubated for either 12, 24 or 48 hours at 37oC with 5% CO2. Concentrations of both TNF- α [523] and 
LPS [489, 491] was obtained from the literature. 
4.2.3 NO Assay  
NO in cell supernatant was quantified using griess reagent. 0.2% napthylethylenediamine 
dihydrochloride was dissolved in deionised water and 2% sulphanilamide in 5% phosphoric acid, the 
two chemicals were stored at 4oC. Before NO quantification both chemicals were mixed in a 1:1 ratio 
to make the griess reagent, cell supernatant was added directly to the reagent in a 1:1 ratio. The media 
and reagent were incubated for 10 min then the absorbance measured at 540 nm using bottom optics. 
Clear 96 flat bottom well plates (Corning Costar) were used on a BMG Labtech FLUOstar Omega plate 
reader. 
4.2.4 Flow Cytometry 
Flow cytometry was conducted using a Guava 8HT. Cells were trypsinized, washed in 10 mM PBS 
(without Mg and Ca) and fixed in 4% paraformaldahyde for 10 min at 4oC, then washed in 1% BSA in 
PBS and stored at 4oC until ready to use. To permeabilise the cell membrane they were incubated in 1 
mL of 100% ice-cold methanol for 10 min at -20oC, then washed in 1% BSA in 10 mM PBS twice. The 
cells were incubated in 5 µg/mL anti-GFAP monoclonal antibody, conjugated to alexa fluro 488 in 1% 
BSA in 10 mM PBS for 30 min in the dark at 4oC. Cells were washed in 10 mM PBS, filtered using 96 
83 
 
well plate mesh cell strainers (Merck Millipore) then analysed using Guava 8HT flow cytometer, 50,000 
events were recorded for every sample. All events were gated, and the mean green fluorescence 
determined using GuavaSoft 2.7 
4.2.5 miRNA Transfection 
Cells were seeded at 20,000 cells/cm2 into 6 well plates, left to attach then activated for 24 hours. All 
transfections were completed using Lipofectamine RNAiMAX following the manufacturers protocol. 
In brief the miRNA was over-expressed by transfecting with the Lipofectamine complex and 
Dharmacon siRNA for 5 mins in serum-free media and RNAse-free water. The complex was then added 
to cell supernatant which included FBS. The transfection media was incubated on the cells for 24 
hours, then the supernatant aliquoted and frozen at -80oC until further analysis, and the cells were 
fixed with 4% PFA for 15 mins. 
4.2.6 Methylene Blue Assay 
Cells were fixed in 4% PFA for 10 mins at 4oC then washed three times in 10 mM borate buffer (10 M 
boric acid was adjusted to pH 8.6 then diluted to 10 mM). 1 mg/mL of methylene blue was diluted in 
10 mM borate buffer and incubated on cells for 30 mins at room temperature. After washing three 
times in 10 mM borate buffer the methylene blue was eluted in 1% HCL (37% concentrated HCL in 
water) in ethanol for 30 min at room temperature. 200 µL of solution from each well was transferred 
into a 96 well plate and the absorbance measured at 650 nm in triplicate. Flat bottom clear 96 well 
plates (Corning Costar) were used on a BMG Labtech FLUOstar Omega plate reader.  
4.2.7 IL-6 ELISA and Luminex Cytokine measurements 
IL-6 ELISA was conducted using the Human IL-6 ELISA Ready-SET-Go kit from Thermo Fisher. The 
manufactures protocol was followed. This included coating the provided 96 well plate with a capture 
antibody and incubating overnight at 4oC, wells were washed 3 times then a blocking buffer added for 
1 hour. A standard curve was made using the provided standards, 100 µL of diluted standards and 100 
µL of the conditioned media was then added to wells. There were three biological replicates all 
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measured in triplicate with a 100-fold dilution (three technical replicates). The plate was then 
incubated overnight at 4oC and wells washed 5 times. The following solutions were then added 
consecutively: detection antibody for 1 hour, avidin-HRP for 30 mins and 1xTMB solution for 15 mins. 
A stop solution was then added, and the plate read at 450 nm using the BMG Labtech FLUOstar Omega 
plate reader. Samples were analysed by averaging the technical and biological replicates then 
comparing absorbance values to the measured standard curve. Significance was tested using a T-Test 
in GraphPad software.   
Luminex measurements were conducted using a custom kit purchased from R and D systems 
measuring: MMP-9, BDNF, GM-CSF, IL-10, G-CSF and IL-1β, following the manufacturers protocol on a 
Luminex Magpix. Initially standards, microparticle cocktail, biotin antibody cocktail and wash buffers 
were prepared as outlined in the manufacturers protocol. Cell supernatant samples were centrifuged 
to remove debris then diluted two-fold. The experiment was conducted in triplicate and each sample 
had duplicate technical repetitions. The assay was conducted by adding 50 µL of the microparticle 
cocktail to each well along with 50 µL of cell supernatant and incubated in the dark for 2 hours on a 
shaker platform at 800 rpm. The plate was washed then 50 µL of the biotin cocktail added, the washes 
were repeated, and the plate incubated in streptavidin-PE for 30 min, both incubations were in the 
same conditions, in the dark at room temperature on a shaker platform at 800 rpm. After incubation 
the samples were read using the Luminex Magpix.  
4.2.8 Metabolite Analysis 
The Roche CEDEX analyser was used to measure the concentration of glutamate, glutamine, glucose, 
lactose and ammonia. Cell number was determined using the methylene blue assay, as explained in 
4.2.6. The specific growth rate was calculated using Equation 8, where: µ is the specific growth rate, 
Cx (t) and Cx (0) are the cell number at the end and start respectively and t is the time in hours [524]. 
𝜇 =
𝐼𝑛 (
𝐶𝑥(𝑡)
𝐶𝑥(0)
)
∆𝑡
       (Eq. 8) 
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Then using the specific growth rate, the specific metabolite flux was calculated using Equation 9. 
Where: qmet is the specific metabolite flux, µ is the specific growth rate, Cx(0) is the cell number at the 
end, Cmet(t) and Cmet(0) is the metabolite concentration at the end and start respectively and t is the 
time in hours [524].  
𝑞𝑚𝑒𝑡 = (
𝜇
𝐶𝑥(0)
) . (
𝐶𝑚𝑒𝑡(𝑡)−𝐶𝑚𝑒𝑡(0)
𝑒𝜇𝑡−1
) (Eq. 5) 
4.2.9 Fluorescent intensity Analysis using Image J  
Fluorescent images were taken using a Nikon Ti microscope using the same exposure time. The 
exposure time was set to the condition with lowest concentration of fluorescent tags. The same 
exposure time was then used for all further conditions and contrast settings were not adjusted. All 
fluorescent image analysis was conducted in Image J. Image J was used to identify the intensity of the 
fluorescence in the images after transfection into cells and the amount of area the fluorescence 
covers. The method used to analyse the images is referenced in Jenson et al [525].  
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4.3 Results 
4.3.1 Astrocyte Activation 
4.3.1.1 NO Assay 
The astrocytoma cells were cultured in media supplemented with LPS, TNF-α and in combination for 
12, 24 and 48 hours. The conditioned media was tested for NO then the cells fixed with 4% PFA for 
methylene blue analysis. Figure 27 shows a significant difference in NO with all conditions and time 
points. The NO increase was still significant when normalised to cell number (Figure 27) except for 
TNF-α at 48 hours. There is a significant decrease in NO production per cell between 24 and 48 hours, 
this could be due to the increased cell number and therefore the reduced concentration of LPS and 
TNF-α per cell. The cell number is 3x higher at 48 hours when compared to 24 hours and therefore per 
cell the concentration of both LPS and TNF-α is 3x lower per cell.  
 
Figure 27: a) Absorbance values for NO in cell supernatant, b) cell number analysed through a methylene blue assay and c) NO 
in cell supernatant normalised to cell number. All significance testing (ANOVA) is in comparison to control at the same time 
point. All graphs show mean ±SD, n=3. (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001) 
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Figure 28: Pictures showing morphology of control astrocytes and activated using LPS and TNF-α, Pictures not 
taken from the same experiment as Figure 27 
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4.3.1.2 GFAP Flow Cytometry 
All conditions were tested for an increase in GFAP expression. Initially a fluorescently conjugated GFAP 
antibody titration was conducted, results shown in Figure 29. The titration shows an increasing 
median fluorescence with concentration. From the titration a 5 ug/mL antibody concentration was 
used in all further experiments, as 5 ug/mL show a jump in green fluorescence when compared with 
the negative control and there was reduced risk of non-specific binding. The astrocytes were then 
incubated with TNF-α/LPS for 24 and 48 hours. Results in Figure 30 and Figure 31 show a small increase 
at 24 hours and a decrease at 48 hours.  
 
Figure 29: Antibody titration for cells stained with, anti-mouse GFAP monoclonal antibody, conjugated to alexa 
fluro 488 (thermo fisher 53-9892-82) 
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Figure 30: GFAP flow cytometry results from 48-hour activation with LPS and TNF-α. a) side and forward scatter 
to illiterate gating, b) side scatter and fluorescence for unstained cells, c) stained cells and d) activated with LPS 
and TNF-α  
 
Figure 31: Mean intensity fluorescence for cells stained with GFAP. SD data obtained from Guava 8HT software 
  
90 
 
4.3.1.3 IL-6 ELISA and Metabolites 
Cells were incubated in TNF-α, LPS and TNF-α/LPS and analysed for IL-6 production. Figure 32 shows 
a significant increase in IL-6 production per cell at all time points.  
 
Figure 32: a) IL-6 concentration in cell supernatant at different time points, b) cell number analysed using 
methylene blue assay and c) IL-6 concentration in cell supernatant normalised to cell number. (ANOVA *p ≤ 
0.05, **p ≤ 0.01 and ****p ≤0.0001, n=3, one experiment in triplicate). Graphs show the mean ±SD. 
 
4.3.2 miRNA Transfection 
Before transfection of miRNA into the activated astrocytes the transfection protocol was tested using 
a miRNA sequence with a fluorescent tag (no access to sequence, has a Dy547 tag 
absorbance/emission 557/570), the sequence is not expected to effect human cells. The sequence 
was transfected into U373 cells using the transfection reagent Lipofectamine RNAiMAX and images 
taken at different time points. Figure 33 shows the different concentrations of the fluorescent 
sequence in astrocytes over 72 hours. Image J analysis on the images in Figure 33 show a significant 
increase in fluorescent intensity with the concentration of fluorescent RNA, R2 values for 24 hours, 48 
hours and 72 hours were all 0.95 (Figure 34). Figure 34 shows significant differences in cell number 
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therefore the fluorescent intensity per cell was calculated with R2 values above 0.91 and p≤ 0.01 for 
all time points.   
The stability of the sequence after addition to cells was evaluated by measuring the fluorescent 
intensity at 24, 48, 72 and 120 hours. Assuming the RNA sequence degrades at the same rate as the 
fluorescent tag, Figure 35 shows a clear significant decrease in fluorescent intensity. However, the % 
area only shows a significant decrease at 120 hours. 
 
Figure 33: Images of U373 cells after transfection with differing concentrations of a miRNA sequence with a 
fluorescent tag using lipofectamine RNAiMAX. Experiment run in triplicate with 3 pictures analysed for each 
run.  All exposure times are the same. 
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Figure 34: Image J analysis of images in figure 4.3.2a. a) and c) intensity values from image J analysis (analysed 
as indicated in [1], b) cell number determined using the methylene blue assay, d) intensity from image J per cell 
from methylene blue analysis. For a and b statistical significance determined using ANOVA and graph c) 
correlation analysis shows significance for 24, 48 and 72 hours (* p ≤ 0.05). Graphs show the mean value ±SD, 
n=3, one experiment run in triplicate. 
 
  
Figure 35: Image J analysis of 20 pM fluorescent miRNA transfected with lipofectamine RNAiMAX reagent 
taking pictures at 24, 48, 72 and 120 hours. a) fluorescent intensity analysis, all significant values are in 
comparison to 24 hours and b) % area. Significance determined using ANOVA. Graphs show the mean value 
±SD, n=3, one experiment run in triplicate  
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4.3.3 Astrocyte Activation and miRNA Transfection 
To determine the effect of overexpressing mir-30c, mir-210, mir-27b, mir-223 and mir-425 in activated 
astrocytoma cells, the cells were activated for 24 hours then incubated with the miRNA sequence for 
24 hours. Cell supernatant was analysed for NO, MMP-9, BDNF, GM-CSF, IL-10, G-CSF, IL-1β and 
metabolites including glucose, glutamate, glutamine, lactate and ammonia to determine the effect. In 
AD astrocytes are activated, therefore the cells were incubated with LPS and TNF-α before adding the 
synthetic miRNA, activation was for 24 hours as the expression of both NO and IL-6 was at its max. 
The cells were transfected for 24 hours as the experiment conducted in Figure 34 show successful 
transfection of the fluorescent sequence, and experiments show increased IL-6 and NO after 48 hours. 
Figure 36 shows no significant change in NO secreted after transfection with all miRNAs after 
normalisation to cell number, however, there is a clear increase between negative (NC) and positive 
(PC) controls. In the NC there was no activating factors (LPS and TNF-α) or miRNA transfection, for the 
PC cells were activated but no transfection. For the scrambled control (SC) the astrocytes were 
activated then transfected with a sequence which should have no effect.  
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Figure 36: Analysis of a) NO in cell supernatant using griess reagent, b) cell number using a methylene blue 
assay and c) NO in cell supernatant normalised to cell number. All significance analysis (ANOVA) is in 
comparison to PC. NC: negative control, PC: positive control and SC: scrambled sequence. ( **p ≤ 0.01, ***p ≤ 
0.001  and ****p ≤0.0001, n=3, one experiment run in triplicate). 
 
Luminex analysis was conducted on cell supernatant, shown in Figure 37 and 39, there was a 
significant increase in all factors after activation with LPS/TNF-α. For the NC, IL-10, IL-1B and MMP-9 
were below the detection limit of the assay. Figure 39 shows after comparison with the scrambled 
control (SC) only mir-210 had a significant effect on the secretion of G-CSF.  
Metabolites were measured in the cell supernatant, and the specific metabolite flux calculated, shown 
in Figures 38 and 40. After activation there is a significant increase in glucose consumption, decreased 
lactate production, decreased glutamate consumption, decrease ammonia production and decreased 
glutamine consumption. After transfection with miRNA sequences mir-223 significantly decreased the 
secretion of glutamate.    
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Figure 37: Luminex analysis of cell supernatant after activation of astrocytes with LPS/TNF-α for 24 hours. 
Statistical significance was determined using t-test. NC: negative control (no activation factors) and PC: positive 
control (activation factors). (* p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001). Graphs show the mean 
±SD. (n=3, one experiment run in triplicate) 
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Figure 38: Luminex analysis of cell supernatant after activation and transfection of astrocytes with miRNA 
sequences. All statistical significance is in comparison with the SC using AVOVA. SC: scrambled sequence. 
(*p≤0.05). Graphs show the mean ±SD. (n=3, one experiment run in triplicate) 
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Figure 39: Metabolite analysis of cell supernatant after activation of astrocytes. Statistical significance was 
determine using t-test. NC: negative control (no activation factors) and PC: positive control (activation factors). 
(* p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001). Graphs show the mean ±SD. (n=3, one 
experiment run in triplicate) 
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Figure 40: Metabolic analysis of cell supernatant after activation and transfection of astrocytes with miRNA 
sequences. All statistical significance is in comparison with the SC using AVOVA. SC: scrambled sequence. (* p ≤ 
0.05). Graphs show the mean ±SD. (n=3, one experiment run in triplicate) 
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4.4 Discussion  
4.4.1 Astrocyte Activation 
Experiments showed incubation of astrocytes in LPS/TNF-α leads to a significant increase in NO, IL-6, 
MMP-9, BDNF, GM-CSF, G-CSF, IL-10 and IL-1β. GFAP expression increased slightly at 24 hours and 
decreased at 48 hours.  Metabolites showed an increase in glucose consumption, decrease in lactate 
and ammonia production and decrease in glutamate and glutamine consumption.  
In the literature LPS has been found to increase the secretion of NO [497, 498], IL-6  [499-501], MMP-9 
[294], BDNF [526], IL-10 [527] and IL-1β [526]. TNF-α increases the secretion of NO [499], BDNF [528], 
G-CSF and GM-CSF [513, 514]. In the brain of AD patients IL-1β and IL-10 increases and BDNF 
decreases. Therefore astrocytes may contribute towards the elevated IL-1β and IL-10, along with 
activated microglia which also secrete IL-1β [529] and IL-10 [530]. The literature shows both GFAP 
increase [496] and decrease after LPS stimulation [497], and decrease after TNF-α incubation [498, 
531].  
The literature suggests that when astrocytes are incubated with LPS it causes induction of NO which 
increases glucose uptake through GLUT 3 receptors, which may cause increased glycolysis [532]. TNF-α 
has also been found to increase glucose uptake by astrocytes [533]. The increased glucose 
consumption found in experiments agrees with the literature. Generally, if there is an increase in 
glucose consumption there is an increase in lactate production [534], this was not found in 
experiments as lactate production significantly decreased. After consumption of glucose astrocytes 
can convert the glucose to glycogen, this would result in no lactate production [94, 534]. One 
hypothesis could be that the increased glucose taken up by astrocytes was converted to glycogen, 
although no evidence of increased glycogen storage in activated astrocytes could be found in the 
literature.  
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In AD there is a build-up of extracellular glutamate, this corresponds with experiments that showed 
decreased glutamate consumption, and therefore reduced neuronal support. Incubation of astrocytes 
with LPS shows no significant change in glutamate release below 30 µg/mL [535, 536], and incubation 
in TNF-α at 50 ng/mL leads to an increase in secreted glutamate due to reduced levels of glutamate 
synthase [537] the enzyme responsible for converting glutamate to glutamine.  
4.4.2 miRNA Transfection 
Activated astrocytes were then transfected with miRNA, however the transfection itself was found to 
have a significant effect on the secretion of MMP-9, BDNF, GM-CSF, G-CSF and IL-1β and lactate 
production, glutamate consumption and ammonia production. This was determined from the 
significant difference between the SC and PC, the SC should have no effect on the factors tested. 
Results showed that mir-210 positively regulates G-CSF. Levels of G-CSF in the AD brain could not be 
found in the literature. In a healthy brain G-CSF controls the differentiation and proliferation of 
neuronal stem cells and deficiencies have been found to disrupt memory formation due to reduced 
levels of binding to NMDA receptors [538] and G-CSF overexpression has been found to improve 
cognitive impairment [516].  
mir-223 negatively regulates glutamate consumption and has been found to control the expression of 
NR2B and Glut2 (glucose transporter 2) [458]. The literature shows mir-223 increases in the brain of 
AD patients [428], so would lead to lower glutamate receptors NR2B and Glut2 [458]. Lower NR2B and 
Glut2 mRNA levels have been found in the AD post-mortem brain [539, 540]. Lower glutamate 
receptor levels could lead to lower glutamate consumption, as shown in Figure 40. 
Astrocytes were chosen as their activation is an early pathological marker of AD and astrocytes are 
the most common cell type in the brain. It was decided not to use neurons as their number decreases 
during the progression of the disease. The cell line used was the U373, this was because it was human 
and well characterised in the literature [491, 496, 499] There are limitations in the conclusions due to 
the human astrocytoma cell line used. Cell lines have proved useful as they have a longer lifespan, 
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cheaper to culture and there are no ethical considerations. They also provide a pure population which 
leads to more consistent and reproducible results. Although the distinct limitation is that cell lines do 
not mimic primary cells. [541]. The conclusions also suffer from the simplistic model used, as there 
was no microglia or neurons. The lack of neurons in the model would impact the regulation of 
glutamate.  
No significant differences were found after over-expressing mir-425, mir-27b and mir-30c in the 
astrocytes. This could have been because they have no target mRNA sequences that are expressed in 
astrocytes. Another reason could be because that the 24-hour incubation time may not have been 
long enough to see an effect. If more time were available an experiment would have been conducted 
to investigate different time points. This work could also be developed by inhibiting the miRNA to see 
if the opposite response could be found. Further work would be to repeat experiments with primary 
cells from multiple donors, expand the model to include microglia and astrocytes or use a more AD 
relevant way of activating the astrocytes. 
4.5 Conclusions  
The objective of the chapter was to identify the role of mir-210, mir-27b, mir-30c, mir-425 and mir-223 
in activated astrocytes and how this could impact AD progression. It is concluded from the results that 
mir-210 positively regulates G-CSF and mir-223 negatively regulates glutamate consumption with 
G-CSF having a beneficial effect and the disruption to glutamate consumption impacting astrocytes 
support to neurons. From the factors tested mir-27b, mir-30c and mir-425 showed no effect on the 
activated astrocytes.  
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Chapter 5: Quantification of 
single stranded DNA using a 
Quartz Crystal Microbalance 
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5.1 Introduction 
5.1.1 Aim of the Chapter 
If a miRNA biomarker in the peripheral blood is developed which could identify AD patients at risk of 
having the pathological characteristics present in the disease. Then there needs to be a cheap, fast 
and reliable diagnostic system that can screen patients for the marker This chapter aims to explore 
the feasibility of using QCM to quantify miRNA as a biomarker to diagnose AD, with the view of using 
QCM as a viable diagnostic system. 
5.1.2 Background 
miRNA can be quantified using PCR, microarrays and NGS, however, in the systematic review 
conducted the predominant quantification method was PCR (see Chapter 2 Table 5). Using this 
method there was inconsistencies in miRNA results from different articles, as shown in Chapter 2 Part 
2.3.3.2. Limitations of PCR include the expense, time for analysis, training required, it’s susceptibility 
to contamination and PCR cannot detect novel sequences [542].  
QCM in comparison to PCR has the potential to be more advantageous in a clinical setting for various 
reasons. Firstly the testing time can be reduced in three ways, one because measurement time is 
quicker as detection can be within 30 mins, it requires minimal  sample  preparation when using 
biological samples and there is less operator involvement so the system would be less susceptible to 
contamination and there would be minimal training required [400, 543, 544]. Other advantages of 
QCM include: its potential for label-free detection [545], as direct detection can achieve limits in the 
low µM range  [397] and its high specificity as the technique can distinguish single base mismatches 
for both miRNA and ssDNA [397-399]. Along with the evidence that QCM can detect miRNA spiked 
into samples made up off 75% human serum [396]. Finally, for QCM to be viable in a clinical setting it 
needs to be compact with an easy set-up which QCM could achieve, and the QCM crystals with 
attached surface functionalisation can be stable for up to 30 days when stored in air or nitrogen [546, 
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547]. QCM has potential in the detection of miRNA sequences, this chapter attempts to prove this by 
using ssDNA sequences of a similar length to miRNA. It was chosen to use ssDNA for the proof of 
concept and testing as this eliminated the need to ensure all equipment be RNAse-free and therefore 
reduce the variability from nucleic acid degradation, also DNA sequences have a lower cost.  
The first step to investigate QCM for ssDNA detection was to ensure attachment of a capture sequence 
to the crystal surface. The role of the capture element was to tether the analyte to the crystal surface 
so measurements can be taken. Two different functionalisation strategies were used to attach the 
capture element to the QCM crystal surface. These were the use of thiolated DNA and biotinylated 
thiols, both these strategies are explained in section 5.2.3. To monitor the functionalisation of the 
capture element to the QCM crystal several techniques could have been used, some of these include 
x-ray photoelectron spectroscopy (XPS), electrochemistry, QCM, QCM-D or SPR. The chapter uses XPS, 
QCM and electrochemistry as these were the techniques available.  
The detection limit of the technique is important as up to 80 pg/mL of miRNA can be found in serum 
which contains around 270 different miRNA sequences, if it could be hypothesised that each miRNA 
is expressed equally, there would be roughly 0.3 pg/µL of an individual miRNA in serum. If the 
detection system used a total of 300 µL of sample that is a total of 90 pg of miRNA, this is 130 pM 
(when using a molecular weight of 6960 Da, the molecular weight of the ssDNA used in the chapter). 
The literature suggests label-free detection limits for QCM are in the low µM range. Therefore, 
amplification strategies were also investigated. 
Two different amplification strategies were investigated: the use of electrochemical quartz crystal 
microbalance (EQCM) and the use of particles. EQCM has been in publications since the 1980’s and is 
the combination of electrochemical techniques with QCM. EQCM takes advantage of the gold 
electrodes on the surface of the QCM crystal, as electrochemistry can be used to add a potential to 
this electrode, the added potential could alter the molecules attached to the crystal surface or the 
properties of the liquid. The QCM can then monitor these changes using the resonant frequency.  The 
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technique is generally used to both change and monitor the change in monolayer surfaces [548], for 
example self-assembled monolayers can be desorbed from the surface of the QCM crystal using 
increased voltages, then the change determined using the resonant frequency [549] or 
electroconductive polymers can be polymerised using electrochemical techniques and the 
polymerisation monitored using the change in resonant frequency [550]. 
In the literature, the use of EQCM in DNA detection is limited when compared to techniques like 
QCM-D or SPR. There is evidence of EQCM being used to improve functionalisation of QCM crystals 
with capture elements, by applying a potential to the electrode that will attract the elements to the 
surface of the crystal, and the attachment of the elements measured using the resonant frequency. 
EQCM has also been used to increase the efficiency of  analyte ssDNA binding to the capture element 
using applied potential [551, 552].  
The use of particles for amplification of signals has been extensively used not just for QCM but in other 
techniques like SPR and electrochemical systems [396, 399, 401, 416-418, 553-558]. Generally, 
particles are used to label the analyte sequence to increase the signal generated from the analyte. The 
addition of particles can mean detection of ssDNA sequences down to 10 aM, within the detection 
range of 130 pM calculated.  
5.2 Materials and Methods 
An argon plasma cleaner (Harrick Plasma) with pressure sensor and Palmsens 3 potentiostat (Alvatek) 
was used during crystal cleaning. AT cut 14.3 MHz quartz crystals with a gold top and bottom electrode 
(diameter of 8.3 mm and a thickness of 115 µm from Laptech) were used. The QCM network analyser 
was built in house, the same network analyser used in the following references [559-563]. 
Infuse/withdraw syringe pump obtained from Harvard Apparatus. Acetone, absolute ethanol, 
propan-2-ol, streptavidin, 6-mercaptoethanol (MCH), potassium ferricyanide (III), potassium 
hexacyanoferrate (II), tris(2-carboxyethyl)phosphine hydrochloride solution (TCEP), sodium chloride 
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(NaCl), Dynabeads M-270 streptavidin and magnesium chloride (MgCl2) were all purchased from 
Sigma Aldrich. The nucleic acid sequences used in experiments included: synthetic biotinylated DNA 
(Sequence: AGAGGTAGTAGGTTGCATAGTT[biotin]), synthetic thiolated DNA (Sequence 5’ to 3’: 
AACTATGCAACCTACTACCTCTTTTT[Thiol-C3]), complementary DNA for thiolated surface (Sequence 5’ 
to 3’: AGAGGTAGTAGGTTGCATAGTT), complementary DNA for biotinylated surface (Sequence 5’ to 
3’: CAATATGCAACCTACTACCTCT), negative control sequence (Sequence 5’-3’: 
GAACTATCGATCACCGATCTCA), were all procured from Sigma Aldrich. Biotin thiol 
(HS-(CH2)11-EG6-Biotin), carboxylic acid thiols (HS-(CH2)11-EG6-OCH2-COOH) and methoxy thiol 
(HS-(CH2)11-EG3-OMe) were from Prochemia surfaces. Ethylenediaminetetraacetic acid disodium salt 
dehydrate (EDTA), tris-EDTA buffer (TE Buffer), PBS tablets obtained from Fisher Scientific. 
Electrochemical RE-1B and RE-1S Ag/AgCl reference electrodes from Cambria Scientific.  
5.2.1 Experimental set-up 
The QCM set-up needed to be altered to allow for electrochemical measurements, so both 
electrochemical and QCM measurements to be taken in parallel.  The experimental set-up for the QCM 
experiments (Figure 40) consisted of a printed circuit board (PCB) which enables the crystal to be 
connected to the network analyser, a spacer to accommodate the depth of the crystal and a flow cell 
with allowances for an O-ring, inlet and outlet channels for liquid flow. This was used as a basis for the 
design of the electrochemical set-up.  
For the electrochemical set-up, shown in Figure 41, the spacer was removed and the diameter of the 
O-ring increased. Holes were inserted in the side and top of the cell to allow for the use of a reference 
and counter electrode. However, in doing this the set-up was no longer compatible with using a 
syringe pump so liquid manipulation had to be carried out through the hole introduced for the 
reference electrode.    
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Figure 41: QCM experimental set-up. a) electrochemistry set-up and b) is the QCM set-up. In both set-up’s a 
crystal is sandwiched between the PCB and flow cell. a) has the addition of a hole in the top and side of the flow 
cell to allow for both counter and reference electrodes. b) has both inlet and outlet to allow for fluid flow. PCB: 
Printed Circuit Board 
5.2.2 Crystal Cleaning 
Crystals were cleaned by sonicating for 5 min in acetone then 5 min in propan-2-ol. The crystal was 
dried with nitrogen and placed in plasma cleaner which uses argon gas (RF power 230 V) for 1 min. 
The process of plasma cleaning the crystal involved creating a vacuum in the plasma cleaner chamber, 
then adding argon gas and switching on the power. The pressure of the argon gas was then increased 
until a white glow was observed around crystal, at this point the timer was set for 1 min (generally a 
pressure around 0.4 mTorr). Argon plasma cleaning was chosen as it is an inert gas so results in no 
chemical alteration to the crystal surface when compared to oxygen treatment which can increase 
oxidation [564]. Immediately after plasma treatment the crystal was immersed in absolute ethanol 
until ready to functionalise.  
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5.2.3 Crystal Surface Functionalisation 
QCM measurements used a quartz crystal with a top and bottom gold electrode. To enable detection 
the gold surface needed to be functionalised with a capture element. This element would selectively 
bind the analyte of choice to the electrode surface. A complementary nucleic acid sequence was used 
as the capture element, this means all nucleic acids between the capture element and analyte base 
pairs matched (see figure 42). The use of a complementary sequence as a capture element has been 
shown in literature [397-399]. The element was attached to the gold surface using thiols, as they form 
a self-assembled monolayer on gold [565, 566]. Two functionalisation strategies were used: thiolated 
DNA and biotinylated thiols as shown in Figure 42.  
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The thiolated DNA surface consisted of the complementary miRNA sequence with thymine bases 
added between the thiol and the complementary sequence. The addition of the thymine bases adds 
a spacer and hydrophilic section which has been shown to prevent non-specific binding [567]. The 
thiolated DNA was then functionalised with a second thiol mercaptohexanol (MCH). The 
Figure 42: Surface functionalisation of QCM crystals both thiolated DNA and biotinylated thiol 
functionalisation. a) is a blank crystal, b) addition of thiolated DNA, c) back filling crystals with MCH, d) 
Detection with ssDNA analyte. Biotin thiol functionalisation corresponds to, f) after incubation with biotin thiol 
and methoxy thiols, g) addition of streptavidin, h) biotinylated DNA functionalisation and i) detection with 
ssDNA analyte. e) depicts the sequences used in the thiolated DNA functionalisation assay, the black sequence 
in the thiolated DNA attached to the crystal surface and the red sequence is the analyte ssDNA. J) depicts the 
sequences involved in the biotin DNA assay, the black sequence is the biotinylated DNA and the red sequence 
the analyte ssDNA. 
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functionalisation of the second thiol had two advantages. One is that nitrogen containing bases in the 
DNA can form self-assembled monolayers with gold, however the affinity is not as high as sulphur, 
therefore the DNA sequences may lie parallel to the surface, the functionalisation with the second 
thiol will prevent this [568]. Secondly, the thiol is a way to control the density of thiolated DNA 
sequences on the surface. The literature suggests that a lower density  of the complementary 
sequence leads to an increase in hybridisation efficiency as it lowers the steric hinderance [569]. The 
thiolated DNA capture element is 9 nm long, therefore is well within the roughly 480 nm penetration 
depth in water (calculated from the equathion located in [570]). 
An alternative functionalisation strategy uses biotinylated thiols, the full functionalisation procedure 
is outlined in Figure 42. Previous studies have been conducted comparing thiolated DNA and 
biotinylated thiol functionalisation techniques and found biotin to be more efficient in detecting DNA 
due to higher hybridisation efficiencies [571, 572]. However, these papers utilised carboxylic acid 
modified thiols and EDC/NHS chemistry to attach streptavidin rather than biotinylated thiols. When 
comparing the use of carboxylic thiols with EDC/NHS and biotinylated thiols, biotinylated thiols were 
found to give a more ordered streptavidin surface and therefore a more ordered attachment of the 
complementary sequence leading to higher hybridisation efficiencies [573]. The biotin thiol surface 
was co-functionalised with methoxy thiols, this lowers the density of biotinylated thiols and therefore 
lowers the steric hindrance. Both methoxy and biotinylated thiols contained ethylene glycol units, 
which has shown to lower non-specific binding of proteins [574]. The length of the biotinylated thiol 
(roughly 5 nm calculated from bond lengths), streptavidin (roughly 6 nm, obtained from [575]) and 
biotinylated DNA (9 nm) was roughly 20 nm, this is well within the penetration depth of the 14.3 MHz 
crystal.  
5.2.3.1 Biotin thiol assay  
The crystal was cleaned as outlined in section 5.2.2 then incubated in an absolute ethanol solution 
containing 10% 0.1 mM biotin thiols and 90% 0.1 mM methoxy thiols for over 16 hours (this ratio was 
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chosen through evidence from literature [410]). The crystal was washed then assembled into a flow 
cell. After assembly the crystal was further functionalised with 10 µg/mL of streptavidin for 30 min, 
then 1 µM biotinylated DNA for 30 min all with a flow rate of 10 µL/min. Detection was conducted 
using the complementary DNA sequence for 30 min. The assay was conducted in 10 mM PBS. (used a 
syringe pump set to withdraw from an Eppendorf tube, through the crystal set-up then into a syringe. 
Pump obtained from Harvard Apparatus).  
5.2.3.2 Thiolated DNA assay 
Before functionalisation crystals were cleaned as outlined in section 5.2.2. Two buffer solutions were 
used for functionalisation as during experiments using the two buffers was found to give a better 
result. The hybridisation buffer (for binding of analyte ssDNA to the capture element) and 
immobilisation buffer (for functionalisation of thiolated DNA to the gold surface of the crystal). 
Immobilisation buffer contained 1x TE buffer, 1 M NaCl, 50 mM MgCl2 and 10 mM EDTA and the 
hybridisation buffer was 1x TE, 1 M NaCl and 0.1 M MgCl2.  
Thiolated DNA was reduced with 0.5 M TCEP in a 1:1 (v/v) ratio for 1-2 hours at room temperature. 
After reduction the DNA was diluted to 1 µM in immobilisation buffer. The crystal was cleaned and 
assembled into the flow cell, the reduced DNA was flowed over the crystal for 30 min, then 1 mM 
MCH diluted in immobilisation buffer for 30 min. For detection hybridisation buffer was flowed until 
baseline stabilisation, the complementary sequence was then diluted in hybridisation buffer and 
flowed over the crystal for 30 mins, the assay was conducted at flow rate of 10 µL/min (used a syringe 
pump set to withdraw from an Eppendorf tube, through the crystal set-up then into a syringe. Pump 
obtained from Harvard Apparatus).  
Thiolated DNA was also functionalised to the surface while a potential was applied to the gold 
electrode on the crystal. The functionalisation under potential involved incubating the crystal in the 
reduced thiolated DNA solution while assembled in the electrochemical flow cell under a voltage of 
0.08 V, this was for 30 min. The crystal was then washed three times in PBS and incubated in 1 mM 
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aqueous MCH for 30 min and washed again. For detection the crystal was washed in hybridisation 
buffer three times and scans taken before hybridisation, then the complementary sequence was 
spiked in hybridisation buffer and left for 30 min. This assay was not conducted under flow using a 
syringe pump as the assay used the electrochemical set-up, therefore baseline stabilisation was not 
conducted, multiple scans were taken and then averaged.  
5.2.4 Electrochemical Measurements 
All measurements were conducted using a Palmsens 3 Potentiostat, platinum counter electrode, silver 
chloride reference electrode and the gold crystal working electrode. Cyclic voltammetry and 
impedance spectroscopy scans were taken in 5 mM K3[Fe(CN)6] and 5 mM K2[Fe(CN)6] in 10 mM PBS. 
Cyclic voltammetry was conducted from -0.1V to 0.6V at a scan rate of 0.03 V/s. Impedance 
spectroscopy was at a DC voltage of 0.0V with open circuit potential and AC of 0.01 V from 50 MHz to 
0.1 Hz.   
5.2.5 EQCM Scan 
For the EQCM scans cyclic voltammetry was set from -0.15 V to 0.6 V at a step of 0.0025 V and scan 
rate of 0.005 V/s. When the potential reached -0.1 V, 0.1 V, 0.3 V and 0.5 V in cyclic voltammetry a 
QCM frequency sweep was taken with a scan rate of 0.1 s and amplitude of 0.6 a.u. 
5.2.6 X-ray Photoelectron Spectroscopy  
The experiment was conducted on a Thermo Scientific K-Alpha XPS. Samples were surveyed and 
high-resolution analysis for C1s, Au4f, S2p and O1s. Three crystals were analysed: crystal 1 was clean, 
crystal 2 was functionalised with 1 mM 10% carboxyl terminated thiols and 1 mM 90% methoxy 
terminated thiols diluted in absolute ethanol overnight at room temperature, and crystal 3 
functionalised with the same surface then cleaned. Results were then normalised to the Au4f peak.   
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5.2.7 Contact Angle 
Measurements were taken using a Data Physics OCA 20. Crystals were washed in water three times, 
left to equilibrate in air for 2.5 min to ensure evaporation of ethanol before water contact angle taken. 
A 0.5 µL drop of water was added to the crystal surface and measurements were taken immediately. 
Three drops were added to each crystal, and the angles of each drop were measured three times. The 
corresponding OCA software was used to determine the contact angle, the ɣsv/ɣsl and ɣlv lines (as 
shown in figure 43) were fitted manually from a photo of the drop, the software then calculated the 
contact angle at the right and left hand side of the drop.   
 
Figure 43: Diagram of the Youngs Laplace equation used to determine contact angle. 
 
5.2.8 Streptavidin Bead Assay  
The Dynabeads ssDNA manufacturer’s functionalisation procedure was followed. In brief 2 x buffer 
and wash (B&W) solution was made up and sterile filtered. Beads were diluted 1:1 in B&W then an 
equal volume of 1 µM biotinylated DNA was added and incubated for 10 min with agitation. The 
solution was then washed twice in B&W and diluted to 107 beads in hybridisation buffer. 
After baseline stabilisation, 600 µL of hybridisation buffer was flowed across the surface for 60 min. 
At 20 min different concentrations of analyte ssDNA was spiked in. At 45 min the streptavidin beads 
functionalised with biotinylated DNA were added and the experiment stopped at 100 min.   
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5.3 Results 
5.3.1 Surface Characterisation 
Surface characterisation was assessed at each functionalisation stage for both the biotinylated thiol 
and thiolated DNA surfaces. Firstly, the cleaning procedure was verified using water contact, XPS and 
electrochemistry to ensure removal of contaminants and to establish the procedures effectiveness in 
removal of thiols. 
5.3.1.1 Crystal Cleaning  
Water Contact Angle 
Water contact angle measurements were taken using 4 crystals in a 2-step procedure. In step 1, crystal 
1 was unclean, crystals 2 and 3 had been cleaned and crystal 4 was functionalised with 10% carboxylic 
acid thiols and 90% methoxy thiols. Results show (Figure 44) a clear significant (ANOVA, p≤0.0001) 
difference between crystal 4 (n=3, CA=29.97o ±SD=1.57) and crystals 1-3 (n=3 CA=85.32 ±SD=6.68, 
CA=75.63 ±SD=1.71, CA=78.37 ±SD=1.50 respectively) indicating attachment of a hydrophilic molecule 
to the surface of the crystal, the molecule could be assumed to be the carboxylic thiol which is 
hydrophilic. No significant difference was found between the unclean and cleaned crystals. 
In step 2 crystal 1 and 2 were washed in absolute ethanol and crystal 3 and 4 were cleaned. When 
comparing crystal 3 (n=3 CA=64.52 ±SD=2.28) which has been cleaned twice and crystal 4 (n=3 
CA=59.82 ±SD=2.35) which was functionalised then cleaned no significant difference was found.  
XPS 
XPS measurements were conducted on three crystals: a clean crystal, a crystal functionalised with 10% 
carboxylic thiols and 90% methoxy thiols and a crystal functionalised with the same surface then 
cleaned (All scan data is in Appendix IV). Results were normalised to the Au4f peak (as shown in the 
literature [576, 577]). Data from the clean crystal (n=1) shows only carbon (normalised Atomic %=0.21) 
and oxygen (normalised atomic %=0.04) elements were present. An increase in all tested elements 
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was seen in the functionalised crystal (n=1) and a clear decease after cleaning (Figure 44), however 
there was not complete removal of thiols as elemental peaks were still present.  
Cyclic Voltammetry  
Cyclic Voltammetry results in Figure 44 shows two distinctive peaks from the reduction and oxidation 
of Fe3+/4+. Theoretical peak current values were calculated from Equation 6 shown in Chapter 2: Ipc 
was 124 mA and Ipa 120 mA. Experimental results show a mean (n=4) Ipc of 149 mA ±SD=11.6 and Ipa 
of 140 mA ±SD=10.3. Leading to a relative error between the theoretical and experimental values of 
16% and 14% respectively.  
From Equation 7 in Chapter 2 the theoretical peak separation was calculated as 57 mV, however the 
experimentally found separation was 93 mV ±SD=0.01 (n=4). The relative error was found to be 63%. 
All impedance spectra fit the randles cell with an Rct value of 79.67 ohms ±SD=27 and Cdl of 71 µF/cm2 
±SD=12 (n=4). 
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Figure 44: Crystal cleaning experiments. A and b) are contact angle measurements 4 crystals were used in a 
two-step experiment. In step 1 crystal 1 was unclean, crystals 2 and 3 were cleaned and crystal 4 was 
functionalised with 10% carboxylic acid thiols and 90% methoxy thiols. Significant differences were found 
between the functionalised surface and all other crystals (**** p ≤ 0.0001). In step 2 (graph b) crystal 1 and 2 
was washed in 100% ethanol, crystal 3 and 4 was cleaned (* p≤0.05, ** p≤0.01). Statistical analysis was 
conducted using ANOVA. c) XPS high resolution analysis of cleaned, crystals functionalised with 10% carboxylic 
acid thiols and 90% methoxy thiols, and crystals functionalised then cleaned, all data normalised to the Au4f 
peak. d and e) electrochemical measurements of cleaned crystals d) cyclic voltammetry and e impedance 
spectroscopy using 5 mM FeII/FeIII in PBS. 
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5.3.1.2 Thiolated DNA 
After cleaning the next step is functionalising the crystal with thiolated DNA. Initially 4 different 
immobilisation buffers were tested using the electrochemical set-up (Figure 41). Buffer A was 10x TE 
buffer, 1M NaCl, 100 mM MgCl2, buffer B: 0.1x TE buffer, 10 mM NaCl, 1 mM MgCl2, 0.1 mM EDTA, 
Buffer C: 1x TE buffer, 100 mM NaCl, 10 mM MgCl2, 1 mM EDTA and buffer D: 1x TE buffer, 1 M NaCl, 
50 mM MgCl2, 10 mM EDTA.  Results show the buffer composition of 1x TE, 1M NaCl, 50 mM MgCl2 
and 10 mM EDTA (Buffer D) gave a 960 ohm ±SD=69 shift in Rct, no other buffer exhibited the same 
change. The experimental protocol was repeated without DNA to ensure there was no buffer effect, 
a significant difference was found (t-test, p ≤ 0.01) between the Rct shift from buffer D with and 
without DNA (Figure 45). 
Crystals were then incubated in thiolated DNA with buffer D overnight to ensure repeatability. Cyclic 
voltammetry measurements resulted in a significant decrease (t-test, p ≤ 0.05) between clean and 
thiolated DNA functionalised crystals in the Ipc (n=4, Ipc=173.96 mA ±SD=14.5 and n=3, Ipc=88.02 mA 
±SD=22 respectively) and Ipa (n=4, Ipa=145.12 mA ±SD=14 and n=3 Ipa=81.41 mA ±SD=24 respectively) 
and a significant increase (t-test, p ≤ 0.01) in the peak separation (n=4, Epc-Epa=0.092 V ±SD=0.01 and 
n=3, Epc- Epa=0.266 V ±SD=0.05 respectively). Impedance spectroscopy data was fitted to the randles 
cell, the Rct increased (t-test, p≤0.05) when the functionalised crystal (n=3, Rct=1026 Ohms ±SD=431) 
was compared to clean (n=4, Rct=70.5 Ohms ±SD=25), all results shown in Figure 45.  
After confirming attachment of thiolated DNA, the QCM set-up was used to optimise the incubation 
time and attachment of MCH. Crystals were assembled into the QCM set-up shown in Figure 41, 1 µM 
thiolated DNA was flowed over the crystal for 30 min then with 1 mM MCH for 30 min until stabilised. 
Thiolated DNA gave a frequency decrease of 260 Hz ±SD=55 Hz (n=3), there was a signal to noise ratio 
of 17. MCH showed a mean frequency increase of 78 Hz ±SD=9 Hz (n=3), all results shown in Figure 
46.  
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Figure 45: Thiolated DNA electrochemical surface characterisation. a) charge transfer resistance data from 
impedance spectroscopy of 4 different buffers Buffer A: 10x TE buffer, 1M NaCl, 100 mM MgCl2. Buffer B: 0.1x TE 
buffer, 10 mM NaCl, 1 mM MgCl2, 0.1 mM EDTA. Buffer C: 1x TE buffer, 100 mM NaCl, 10 mM MgCl2, 1 mM EDTA. 
Buffer D: 1x TE buffer, 1 M NaCl, 50 mM MgCl2, 10 mM EDTA, values extracted by fitting to the randles cell. Graphs 
b, c, d and e are comparisons between clean crystals and functionalised with 1 µM thiolated DNA in buffer D. 
Significance tested using a t-test (** p ≤ 0.01, * p ≤ 0.05). 
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5.3.1.3 Biotinylated Thiols 
Two aspects of biotinylated thiol functionalisation were tested, 1) attachment and 2) whether 
different ratios of biotinylated thiols to methoxy thiols can be added to the surface by changing the 
ratio of thiols in the incubation solution. Results in Figure 47 shows no distinctive iron peaks from 
cyclic voltammetry indicating attachment of thiols. A distinct difference was seen in the Nyquist plots 
(Figure 47). Results show as the ratio of biotinylated thiols increased the charge transfer resistance 
significantly decreased (p=0.0302), but capacitance didn’t significantly change (p=0.1170). Statistical 
analysis was conducted using Pearsons correlation coefficient.  
After attachment of biotinylated thiols, the surface was further functionalised with 10 µg/mL of 
streptavidin then 1 µM biotinylated DNA. Results in Figure 48 show a significant decrease in frequency 
after addition of both streptavidin (-153 Hz, SD=±19.3 Hz, n=3, ANOVA p≤0.001) and biotinylated DNA 
(-116 Hz, SD=35.1 Hz, n=3, ANOVA p≤0.01).  
Figure 46: Thiolated DNA surface characterisation using QCM. a) fundamental frequency shift over time using a flow rate of 
10 µL/min in buffer D at 30 min 1 µL thiolated DNA added and at 55 min 1 mM MCH in buffer D. b) Average frequency shift 
from the addition of thiolated DNA and MCH. 
120 
 
 
 
 
 
 
 
Figure 47: Biotin thiol electrochemical surface characterisation. a) cyclic voltammograms. b) impedance spectroscopy Nyquist plots 
as the proportion of biotin thiols to methoxy thiols increases. c) charge transfer resistance and d) double layer capacitance data 
extracted from the Nyquist plot. Pearson’s correlation coefficient found a significance of p=0.0302 for graph c and p=0.1170 for 
graph d. (n=3) 
 
 
Figure 48: Fundamental frequency shift of biotin thiol surfaces functionalised with 10 ug/mL of streptavidin for 30 min then 1 
uM of biotinylated DNA was added for 30 min at a flow rate of 10 uL/min. a) surface functionalisation over time and b) average 
frequency shift, significant compared to baseline variation (ANOVA *** p≤0.001, **p≤0.01, n=3). 
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5.3.3 Detection of Small Synthetic Single Stranded DNA (ssDNA)  
After surface characterisation for both thiolated DNA with MCH and biotinylated thiols with methoxy 
thiols the surfaces were tested with the analyte ssDNA, using the same QCM set-up shown in Figure 
41.  Both surfaces were initially tested with 6 µg/mL of ssDNA, then the ssDNA concentration lowered. 
The ssDNA sequence used was let-7d-5p converted to DNA bases, this miRNA has been found to be 
deregulated in the plasma of AD patients [339].   
For the thiolated DNA surface results show a mean fundamental resonant frequency shift of -52 Hz 
(n=3, ±SD=6Hz) for 6 µg/mL of ssDNA. The concentrations of complementary DNA were then lowered, 
concentrations were 6 ng/mL, 60 ng/mL and 600 ng/mL. Results show a mean (n=2) frequency shift of 
5.34 Hz ±SD=4.08, 21.43 Hz ±SD=5.99 and 73.10 Hz ±SD=9.48 respectively. A significant difference 
(ANOVA, p≤0.001) was found for 600 ng/mL of complementary DNA. No change was found when using 
the third resonant frequency current. 
The same complementary sequence was used for the biotinylated thiol surface. 6 µg/mL of synthetic 
DNA resulted in a negative shift of 86 Hz (n=3, ±SD=10 Hz) as shown in Figure 50. For a lower 
concentration of 60 ng/mL the shift reduced to 46 Hz (n=1).  
 
122 
 
 
 
 
  
Figure 50: Fundamental frequency shift 1 6 µg/mL ssDNA added to biotin thiol surface for 30 min at a flow rate of 10 µL/min. a) 
frequency shift over time and b) average frequency shift c) shift in 3f current. NGS: Negative Control Sequence 
 
Figure 49: Fundamental frequency shift after ssDNA added to thiolated DNA surface for 30 min at a flow rate of 10 
µL/min. a) frequency shift over time and b) average frequency shift. Significance tested using ANOVA (** p≤0.01, *** 
p≤0.001). NCS: Negative Control Sequence 
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5.3.4 Signal Amplification 
The evidence suggests ssDNA can be successfully detected using QCM however the limit of detection 
is in the 60 ng/mL range. Total miRNA in the serum of an AD patient is around 80 pg/µL and is 
composed of around 270 different miRNAs, if it is assumed that each miRNA is expressed equally in 
serum then each miRNA would be expressed at 0.3 pg/ µL, this is 200x lower than the detection limit. 
Therefore, to improve the detection limit two strategies were used to amplify the QCM signal for the 
thiolated DNA surface. The first strategy was to alter the transduction technique by using EQCM, the 
second was to add a particle into the assay. 
5.3.4.1 EQCM 
Firstly, an alternative functionalisation strategy was tested, thiolated DNA was incubated with the 
crystal under an applied potential of 0.08 V for 30 min, the graph in Figure 51 shows complete removal 
of the iron peaks. This implies that the crystal surface is completely blocked with thiolated DNA so 
electron exchange between iron molecules and the crystal surface is drastically reduced. Impedance 
spectroscopy was conducted however the curves could not be fitted to the randles cell.  
Functionalisation with thiolated DNA under potential was also detected using EQCM while subjected 
to four potentials: -0.1 V, 0.1 V, 0.3 V and 0.5 V. Figure 52 shows that after functionalisation the 
frequency shift increased, this contradicts experiments conducted without potential in Figure 50 
where the frequency decreased. A small increase was seen after functionalisation with MCH, this 
increase was also seen without potential. The detection of 6 µg/mL of analyte ssDNA using EQCM was 
conducted and resulted in an increase in frequency.  However, there was no significance as the data 
was too variable for the small number of replicates included in the experiment (n=3).   
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Figure 52: Frequency shift after functionalisation with 1 µM thiolated DNA and 1 mM MCH then detection of 6 
µg/mL ssDNA under potential. Significance was calculated by comparing to previous assay stage, e.g 
significance of MCH calculated by comparing to Thiolated DNA  (* p≤0.05, n=3 for thiolated DNA and MCH, n=2 
for 6 µg/mL and n=1 for NCS). 
5.3.4.2 Particle Amplification 
The second amplification strategy was to alter the assay, this was done by using the competitive assay 
shown in Figure 53. The surface was functionalised with thiolated DNA, MCH then the analyte ssDNA 
added. However, an extra step was added, particles were functionalised with the analyte ssDNA and 
flown across the crystal. It was hypothesised that the particles would bind to thiolated DNA not 
Figure 51: Cyclic voltammetry after 6 µg/mL thiolated DNA functionalisation for 30 min in 
buffer D under a potential of 0.08 V. 
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already hybridised to analyte ssDNA. Results show a resonant frequency increase of 322 Hz ±SD=22 
from streptavidin beads when no ssDNA (n=3) was bound to the surface beforehand (no DNA) and a 
frequency shift of 157 Hz ±SD=33 when 1 6 µg/mL of synthetic DNA (n=2) was added beforehand. 
There was a significant reduction in the frequency shift from the particles after addition of ssDNA 
(t-test p≤0.05).   
 
Figure 53: Amplification of ssDNA detection signals using particles. a) schematic representation of thiolated 
DNA surface functionalisation, detection with ssDNA then binding of ssDNA functionalised particles that bind to 
all non-hybridised thiolated DNA. b) binding of ssDNA and ssDNA functionalised particles over time, c) average 
frequency shift (* p≤0.05, for no DNA n=3 and for 6 µg/mL n=2). 
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5.4 Discussion 
The aim of the chapter was to assess the feasibility of using QCM to detect miRNA in physiological 
fluids. The chapter outlined experiments to assess the following: 1) test a crystal cleaning procedure 
to ensure it’s free from contaminants, 2) ensure functionalisation of crystals with thiolated DNA and 
biotinylated thiols and 3) test the functionalised crystal surface with analyte ssDNA to determine the 
detection limit of direct detection. However, the following was not completed: to replicate the testing 
procedure with a miRNA sequence and test the procedure in a relevant physiological fluid..  
5.4.1 Crystal Cleaning 
After crystal cleaning the mean water contact measurement was 76o, in the literature measurements 
are shown to be between 62o – 79.8o for a bare gold surface [578-581]. Therefore, measurements fit 
values seen in the literature. XPS shows the surface had contaminations of carbon and oxygen which 
could be due to unevaporated ethanol. The cyclic voltammetry results (ipc, Ipa and Epc-Epa) are different 
to theoretical values, however this did not affect functionalisation with both thiolated DNA and 
biotinylated thiols.  
5.4.2 Crystal Surface Functionalisation 
Characterisation of the thiolated DNA surface indicated binding. Significant differences were found in 
cyclic voltammetry (Epc-Epa, Ipc and Ipa values), impedance spectroscopy (Rct and Cdl values) and QCM 
(fundamental resonance frequency shift). In cyclic voltammetry lower peak currents and an increase 
in peak separation can be seen in the literature along with the decrease in Cdl and increase in Rct [582, 
583]. Specific comparisons could not be found for QCM measurements with a 14.3 MHz crystal, for 
thiolated DNA on a 9 MHz quartz crystal driven at 27 MHz the average frequency shift was 182 Hz 
[584]. The Sauerbrey Equation (Equation 1) was used to determine the number of thiolated DNA 
molecules attached the crystal surface, this was calculated to be 4.11x1012 molecules.cm-2 which is 
comparable to values found in the literature [585-587].  
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The biotinylated thiol surface was also characterised through electrochemistry and QCM, both 
techniques demonstrated attachment of thiols. Electrochemistry results indicated that the 
biotinylated and methoxy ratio on the crystal surface can be altered by adjusting the incubation 
solution. This has also been shown in the literature by Frederix et al who assessed the ratio of a 
carboxylic acid thiols and hydroxy thiols on a gold surface using cyclic voltammetry [410]. The 
subsequent functionalisation of streptavidin and biotinylated DNA resulted in a decrease in resonant 
frequency, which coincides with results found in literature [573, 588]. 
5.4.3 Analyte detection 
To achieve 100% hybridisation of analyte ssDNA to the thiolated DNA 23.4 µg of DNA would be 
needed, this equates to a frequency shift of 216 Hz. The experimental shift for 6 µg/mL (1.8 µg) was 
52 Hz. This is equivalent to 0.05 µg and therefore a hybridisation efficiency of 24%. This efficiency fits 
with those seen in the literature for the number of thiolated DNA molecules.cm-2 [569].  
For the analyte ssDNA on the biotinylated thiol surface the experimental shift was 86 Hz for 6 µg/mL 
when using biotinylated thiols. 1.02x1013 biotinylated DNA molecules were bound to the surface, for 
100% hybridisation the frequency shift would be 104 Hz, therefore hybridisation efficiency was 
calculated to be 83%. The biotinylated thiol surface resulted in higher hybridisation efficiencies 
compared to thiolated DNA, the same effect was seen in the literature [571, 572].  
5.4.3.1 Signal Amplification 
Both the thiolated DNA and biotinylated thiol surfaces exhibit a frequency shift with 60 ng/mL analyte 
ssDNA. To improve the limit of detection two amplification strategies were tested: using EQCM and 
particles. The use of EQCM gave an increase in frequency, experiments conducted with QCM only gave 
a decrease in frequency and correlated with journals in the literature [589]. Therefore, it was 
determined that the addition of potential to the system resulted in flexible attachment of ssDNA and 
an increase in frequency [559]. The average EQCM frequency shift was 153 Hz and compared to QCM 
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of 86 Hz is 1.7x higher. Therefore, the use of EQCM amplified the signal, however there was low 
repeatability between replicates.  
The binding of particles to the crystal surface also resulted in an increase in frequency. Evidence from 
other studies using the same sized particles (diameter: 2.8 µm) also show an increase in frequency 
[590]. Nanoparticles are extensively used in the literature to amplify ssDNA detection to achieve 
sensitivities in the aM-pM range [553-556]. Particles have the potential to achieve low detection limits, 
although experiments conducted in Figure 53 need further work including increased replicates and 
testing lower concentrations of analyte DNA. 
5.5 Conclusion 
The aim of the chapter was to investigate the feasibility of using QCM as a rapid, sensitive and specific 
detection technique for miRNA. Results show that QCM can detect ssDNA sequences at 60 ng/mL with 
both thiolated DNA and biotinylated thiol surface functionalisation strategies. To further the work 
replicates would need to be conducted on the analyte ssDNA detection step. Before using RNA 
sequences or testing the system in physiological fluid the detection limit would need to be improved. 
It was estimated in section 5.1.2 that the levels of a single miRNA sequence could be roughly 0.3 pg/µL, 
so the detection limit would need to be at least 200x lower. 
Although the ssDNA sequence was the same length as a miRNA sequence just converted into DNA, 
the chapter does not explore binding of natural miRNA sequences. The DNA used was synthetic, the 
molecular structure of DNA and RNA is different, and DNA is negatively charged, all these factors could 
alter the binding of the sequence to the crystal surface. The experiments conducted do not explore 
the specificity of the detection system, this could be tested with sequences which have 1 or 2 bases 
mismatched to the analyte sequence. Evaluating the specificity could be vital due to the similarities 
between miRNA sequences.  
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Chapter 6: Outcomes, 
Limitations and Future 
Directions 
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6.1 Outcomes 
Chapter 3 found no significant difference in the deregulation of mir-210, mir-223, mir-27b and mir-30c 
in the post-mortem brain of AD patients through the progression of the disease. The experiments 
conducted in this chapter were in response the first aim of the thesis. The aim was to analyse the 
miRNA changes in the post mortem brain of AD patients as it was hypothesised that the pathological 
miRNA changes seen in the brain could be reflected in the peripheral blood. Therefore, the strategy 
could be used to identify early deregulated miRNA suitable for biomarker diagnosis. Due to the chosen 
miRNA showing no significant difference through the progression of the disease no potential 
biomarker targets could be identified. This was due to the large standard deviation between the 
patient samples. One reason for the high variation could be the high RNA degradation in the samples, 
other reasons are outlined in the limitations.  
Chapter 4 aimed to investigate if there is a link between overexpressed miRNA and activated 
astrocytes. The second outcome was that mir-210 positively regulates G-CSF and mir-223 negatively 
regulates glutamate consumption in an astrocyte cell line. It is hypothesised that if mir-210 is 
downregulated in the brain and this would decrease the levels of G-CSF which would effect NMDA 
receptors, this can cause disruptions in memory formation. For mir-223 the hypothesis was that the 
increase in mir-223 in the brain could decrease the levels of glutamate receptors and therefore result 
in lower glutamate consumption. The modal used was a cheap and simplistic way of screening more 
miRNA sequences in order to identify potential targets to move forward into a more relevant AD 
modal. The modal did identify 2 miRNA sequences; however, this tells us that these miRNAs could 
impact G-CSF and glutamate consumption, both of which are altered in AD.  
Finally, Chapter 5 and shows that QCM can detect ssDNA sequences down to 60 ng/mL. This work was 
conducted to investigate the feasibility of using a QCM to detect changes in miRNA levels in the 
peripheral blood. The work confirms that QCM can be used to detect ssDNA, however further work 
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including experimental replicates and determining the specificity of the assay would need to be 
conducted to further explore the aim.   
6.2 Limitations 
The biggest limitation in Chapter 3 is in the conclusion that no potential biomarkers for AD were found. 
The biggest limitation in the conclusion is it assumes that the change in miRNA levels in the brain are 
reflected in the peripheral blood. There is evidence to support this assumption [354, 355]. However, 
the literature shows 250 miRNAs are deregulated in the brain of AD patients [430, 433-444] whereas 
only 101 miRNAs have been found in the peripheral blood, so not all miRNA in the brain can be 
reflected in the blood or not all have been found. Other limitations arise from the low number of 
samples, high degradation of RNA and long PMI’s. 
Improvements that would generate the biggest impact to Chapter 3 are related to the experimental 
design. The first would be to look for a biological miRNA reference gene, so that biological variation 
could be accounted for in the analysis. The second amendment would be to have an additional spike 
in control added after homogenising the tissue, this would have accounted for the variability in the 
RNA extraction procedure. Finally, the amount of RNA used in the PCR experiment should have been 
calculated from the amount of small RNA rather than total RNA to reduce the variation in the amount 
of RNA used in the PCR experiment. Changes in these three factors would result in lower variability. 
Other improvements would be to increase the sample size or obtain the samples as RNA lysate rather 
than frozen tissue with PMI’s lower than 24 hours.  
Chapter 4 conclusions suffer from limitations in the cell model used, there are three main reasons for 
this. The first is that the cells in the model were an astrocytoma cell line and not primary human 
astrocytes. The second it the model’s relevance to AD, it would have benefited from activating the 
cells using amyloid-β which builds up inside the brain of AD patients. Finally, the limitation there are 
no neurons. Neurons are an important in the glutamate/glutamine cycle, as neurons convert 
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glutamate to glutamine. Therefore, the biggest impact to the experiment would be to add neurons 
into the model, closely followed by using a molecule more relevant to AD for activation of astrocytes. 
Chapter 5 looked at using QCM to detect changes in miRNA levels in physiological fluid. The biggest 
limitation in the experiment was that ssDNA was used rather than RNA sequences, therefore the 
greatest improvement to the chapter would be to repeat the experiment using a miRNA sequence.  
6.3 Future Work 
6.3.1 Investigate the link between changes in miRNA in the brain and in the peripheral 
blood of AD patients 
The biggest limitation of Chapter 3 was the assumption that changes in miRNA in the brain are 
mirrored in the blood. Therefore, the chapter would benefit from investigating to what degree that is 
true. The experiment could involve obtaining both blood and brain samples from the same patient, 
some blood banks can provide this, then analysing the miRNA using a more high throughput 
technique, for example microarray’s.  
6.3.2 Improve the AD astrocyte cell model 
To investigate the overexpression of miRNA in activated astrocytes it would benefit from a model 
which uses astrocytes and neurons. The role of an astrocyte involves giving support to neurons, so a 
model without neurons would have limitations. So further work could be to develop a neuron and 
astrocyte co-culture cell model. Along with using a molecule to activate the astrocytes which is more 
relevant the AD.  
6.3.3 Improving the detection limit of the QCM assay 
Before conducting more work to make the model more relevant to miRNA detection it would benefit 
from improving the detection limit, as currently the detection system needs to be at least 200x lower. 
This could be done by amplifying the DNA/RNA before detection, improving the transduction 
technique or adding a signal amplification step. 
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Appendix I: 
Alzheimer 
Post-mortem Brain 
Sample Information  
164 
 
Case No. Gender 
Age at 
death 
Clinical diagnosis Braak stage (AD) PMI (h) Av. Brain pH Group* 
DPM09/24 M 78 cognitively normal (age changes only) 0 144 na 2-A 
DPM12/11 M 54 control (age changes only) 0 37 na 2-A 
DPM12/16 F 53 control (age changes only) 0 92.5 na 2-A 
DPM16/06 F 45 control, mild SVD 0 71 5.95 2-A 
DPM16/18 F 94 control, moderate SVD I 58.5 5.88 1 - LPh/LPMI 
DPM12/09 F 87 cognitively normal, mild AD pathology in temporal lobe I-II 87 na 2- B 
DPM12/23 M 95 control (age changes only) I-II 12 na 2- B 
DPM14/27 F 90 normal, mild AD changes in temporal lobe I-II 121 5.81 2- B 
DPM16/38 F 76 MCI (age changes only) I-II 113.5 na 2- B 
DPM16/31 M 90 control (age changes only) I-II 155 5.64 1 - LPh/HPMI 
DPM14/11 M 91 normal, mild SVD I-II 43.5 6.32 1 - HPh/LPMI 
DPM13/12 F 89 normal, mild AD pathology II-III 134 6.35 1 - HPh/HPMI 
DPM10/01 F 78 dementia, moderate Alzheimer's disease,  III-IV 81 na 2- C 
DPM14/01 F 93 probable Alzheimer's disease III-IV 70.5 na 2- C 
DPM14/18 M 77 incipient Alzheimer's disease III-IV 162 6.04 2- C 
DPM16/01 M 90 possible Alzheimer's disease III-IV 26 na 2- C 
DPM16/08 M 88 incipient Alzheimer's disease III-IV 114 5.54 2- C 
DPM16/43 M 87 incipient Alzheimer's disease III-IV 92.5 na 2- C 
DPM13/16 F 89 Dementia, moderate AD pathology IV-V 56 6.36 1 - HPh/LPMI 
DPM13/11 F 96 dementia, moderate AD pathology IV-V 154 6.35 1 - HPh/HPMI 
DPM12/32 M 73 Alzheimer's disease V-VI 36 6.63 2- D 
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Case No. Gender 
Age at 
death 
Clinical diagnosis Braak stage (AD) PMI (h) Av. Brain pH Group* 
DPM15/29 M 81 Alzheimer's disease and Vascular dementia V-VI 68 6.03 1 - LPh/LPMI 
DPM16/14 F 92 Alzheimer's disease V-VI 118 5.94 1 - LPh/HPMI 
DPM09/15 F 89 Alzheimer's disease V-VI 72 na 2- D 
DPM09/17 M 76 Alzheimer's disease V-VI na na 2- D 
DPM10/08 F 87 Alzheimer's disease V-VI 60 na 2- D 
DPM11/16 M 64 Alzheimer's disease V-VI 75 na 2- D 
DPM12/01 M 67 Alzheimer's disease V-VI 84 na 2- D 
 
• Group refers to the experiment the sample was used. Samples with a 1 refer to table 3.2.1a, and samples 2 to table 3.2.1b. LPh = low Ph, HPh = 
high Ph, HPMI = high post mortem interval and LPMI = low post mortem interval. Group A-D refer to Braak stage grouping, A = Braak 0, B = Braak 
I-II, C = Braak III-IV and D = Braak V-VI.   
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Appendix II: Agilent 
Bioanalyser data initial 
8 samples  
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All Agilent Bioanalyser data was gathered using total RNA, on an RNA nano chip. All samples analysed 
showed were determined to contain degraded RNA. The degradation is evident both in the gel and 
electropherogram. It can be seen in the gel as it has a smeared appearance rather than clear bands 
and in the electropherogram from that lack of RNA peaks at high molecular weight and the distinctive 
18S and 28S peaks.   
 
 
  
Sample Number Brain Sample 
1 16.18 
2 14.11 
3 13.11 
4 13.16 
5 13.12 
6 15.29 
7 16.31 
8 16.14 
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Appendix III: 20 
Samples Agilent 
bioanalyser data 
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Chip 1: 
Sample Number Brain Sample 
1 11.16 
2 12.11 
3 10.01 
4 10.08 
5 12.09 
6 12.23 
7 12.32 
8 09.17 
9 16.41 
10 16.06 
11 14.27 
12 09.15 
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Chip 2: 
Sample 
Number 
Sample Name 
1 16/01 
2 16/38 
3 16/08 
4 09/24 
5 12/01 
6 14/01 
7 12/16 
8 14/18 
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Appendix IV: All 
XPS Scan Data 
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Crystal 1: Clean Crystal 
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Crystal 2: Functionalised Crystal 
 
High Resolution Scans: 
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Crystal 3: Functionalised and Cleaned Crystal 
 
High Resolution Scans: 
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